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 The continual emergence of multidrug resistance in bacteria calls for the development of 
novel antibiotics in order to treat resistant infections.  Traditionally, small molecule antibiotics 
have been used as treatment for infections.  However, the emergence of multidrug resistance in 
bacteria encompasses every major class of commercially available antibiotics.  As the need for 
antimicrobials capable of combating multidrug resistant bacteria grows, completely new 
therapeutic paradigms for the treatment of bacterial infections are being explored.  This thesis 
presents one such paradigm in which small-molecule ligands conjugated to gold nanoparticles 
function as novel antibacterial materials.  The goal of this work was to develop the synthetic 
methods necessary for gold nanoparticle library synthesis and purification,  identify gold 
nanoparticle conjugates capable of inhibiting the growth of various strains of bacteria, determine 
nanoscale structure-activity relationships (NSAR) for the most active conjugates, and gain 
insights into the mode of action of these gold nanoparticle conjugates.  Gold nanoparticle 
conjugates capable of inhibiting the growth of various strains of bacteria were identified from an 
initial 120 member combinatorial library.  The activity of the gold nanoparticle conjugates was 
dependent on the chemical functionalities combined on the surface of the gold nanoparticles.  
Preliminary studies identified a lead gold nanoparticle conjugate, designated LAL-32, which 
displayed 99.9% growth inhibition of E. coli at a concentration of 250 nM and a therapeutic 
index of 400. 
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Chapter 1. Introduction 
   1.1 Background  
 Multidrug resistance is a growing threat to global heath.  The emergence of multiple drug 
resistance has made antibiotic drug discovery an increasingly difficult problem to solve.  The 
pharmaceutical battle against drug resistance in bacteria has been waged virtually since the 
release of penicillin in 1941 after its discovery in 1928 by Alexander Fleming
1
. In some cases, 
multidrug resistance only takes a few years to develop in a given strain of bacteria, making what 
was once a new antibiotic on the market quickly obsolete
2
.  Recent evidence of this phenomenon 
was documented in a Mumbai clinic early in 2012, where isolation of a strain of Mycobacterium 
tuberculosis (TB) that is “totally resistant” to all current antibiotic treatments has occurred3.   
 Multidrug resistance in TB is a classic example of resistance evolution.  The World 
Health Organization estimates that about one third of the world’s population is infected with 
TB
4
.  While most of these infections involve a latent form of the bacteria, only to emerge into an 
active infection in about 10% of this population, there are still over 1.4 million deaths worldwide 
each year due to TB infections, with about 10% of these deaths due to multidrug resistant strains 
of TB
4
.  Due to the intrinsic resistance of TB to many classes of antibiotics, treatment involves 
three different antibiotics to target all of the metabolic forms of the bacterium that exist in an 
active infection
5
.  Treatment is extensive, conducted over a course of 9 months.  A few missed 
doses during this long course of treatment can result in the emergence of bacterial resistance to 
the current therapy. Resistant strains of the bacterium often require a more rigorous treatment 
that is also more costly and potentially less effective than the first line antibiotics
6
.  Furthermore, 
with the identification of multidrug resistant strains of TB in nearly every country,
4 
worldwide 
control of TB is threatened.   
2 
 There are four main mechanisms of multidrug resistance in bacteria.  The first 
mechanism of resistance is intrinsic resistance.  This form of resistance is defined by bacteria 
that already possess characteristics that make treatment with antibiotics problematic
7
.  The 
members of the Mycobacterium genus, such as TB possess many structural characteristics, such 
as a thick mycolic acid layer in the cell wall, decreased expression of porins in the cell 
membrane, and increased presence of efflux pumps in the cell membrane to aid in the prevention 
of the action of many antibiotics
8
.   
 The second mechanism of multidrug resistance in bacteria is mutation of the target.  
Examples of this mechanism are the penicillin binding proteins of the Staphylococcus genus
9
.  
Penicillin binding proteins (PBPs) are essential to the proliferation of the bacteria and are 
involved in cell wall biosynthesis.  The cell wall consists of a thick peptidoglycan layer, which 
surrounds the Gram-positive bacterium and is responsible for protecting the bacterium against 
the extracellular environment.  Penicillin’s mode of action against Staphylococcus aureus is to 
bind to the active site of PBPs and inhibit cell wall biosynthesis.  This causes the bacterium to 
have a weakened cell wall, which ultimately gives rise to cell lysis
10
.  The emergence of 
methicillin resistant Staphylococcus aureus is due to the acquisition of a new penicillin binding 
protein, called PBP2a
11
.  This PBP is encoded by the mecA gene, which resides within the 
Staphylococcal cassette chromosome mec.  Once this mobile genetic element has been integrated 
into the bacterial chromosome, expression of PBP2a can occur, which has a mutated active site 
that displays low affinity for β-lactam antibiotics.  PBP2a becomes the predominant functional 
PBP under these conditions, allowing for cellular proliferation in the presence of β-lactam 
antibiotics
11
.   
3 
 A third resistance mechanism is enzymatic inactivation, where the bacteria express 
enzymes that chemically modify the antibiotic drug so that antimicrobial activity is lost.  
Examples of this class of multidrug resistance include the RTEM-1 β-lactamase of Escherichia 
coli
12
 and the PC1 β-lactamase of Staphylococcus aureus13.  β-lactamases are proteins that bind 
β-lactam antibiotics and catalyze the hydrolysis of the β-lactam ring, rendering the released 
product inactive. 
 The fourth mechanism of resistance in bacteria are efflux pumps.  Efflux pumps are 
native proteins that exist in the cell membrane of bacteria and are responsible for exporting toxic 
molecules from inside the cell
14
.  Included in this list of toxic molecules are antibiotics, many of 
which have intracellular targets.  Extrusion of the antimicrobials from the intracellular space of 
the bacterium inhibits the activity of these molecules since they cannot access their cellular 
target.  Multidrug resistance arises from either the overexpression of efflux pumps or from the 
expression of specific classes of efflux pumps
15
.  Overexpression allows for a faster rate of 
extrusion of toxic molecules from the intracellular space, while expression of certain classes of 
efflux pumps involves a more regulated cell process.  For example, the MepA multidrug efflux 
pump of Staphylococcus aureus
16
, part of the multidrug and toxic compound extrusion family of 
efflux pumps, is regulated by a regulator protein called MepR.  Natively, MepR is bound to the 
promoter region of the MepA gene, inhibiting expression of the efflux pump.  Once a drug 
molecule binds the repressor, dissociation of the repressor from the promoter segment of DNA 
occurs, allowing for transcription of the MepA gene
16
.   
 There are many different classes of antibiotics.  However, antibiotics must selectively 
target essential bacterial processes.  There are five main bacterial targets: cell wall biosynthesis, 
DNA and RNA synthesis, protein synthesis, and intermediary metabolism
17
.  As resistance to 
4 
antibiotics expands, new therapies have emerged in order to address the ineffectiveness of 
current antibiotics against resistant strains of bacteria.  An example is combination therapy
18
, 
where two different classes of antibiotics are administered to the infection to target two different 
essential bacterial processes.  The rationale is that targeting multiple processes at the same time 
will limit the evolution of resistant strains.  Alternatively, different materials have been 
investigated, such as a silver antimicrobial gel
19
.  Silver ions have been shown to display 
antimicrobial properties.  This material has been applied to the prevention of infections in burn 
patients.      
   1.2. Gold Nanoparticles 
 In an effort to highlight the seriousness of the bacterial multidrug resistance problem, 
GlaxoSmithKline conducted a study in the late 1990s-early 2000s, which appeared in Nature 
Reviews in 2007
20
.  During this study, GlaxoSmithKline’s Beecham organic compound library 
of 260, 000 to 500, 030 compounds was screened against a variety of bacterial genes in a series 
of 67 high throughput screening campaigns. The results yielded only a few potentially useful 
targets.  Payne et al concluded that continuation along this process of antimicrobial drug 
discovery was both costly and impractical.  Therefore, a new method of antibiotic drug discovery 
was necessary
20
. 
 Aware of this problem, many researchers are now attempting to employ alternative 
materials instead of small molecules to address the issue of multidrug resistance in bacteria, such 
as organic and inorganic nano-materials
21, 22, 23
.  Gold nanoparticles in general are of interest due 
 
5 
to the variety of shapes available synthetically, such as spheres, rods, triangles, and cubes,
24
 in a 
range of sizes.  Gold nanoparticles are gold clusters passivated by different ligands, such as 
citrate, triphenylphosphine, and organothiol ligands (Figure 1.1).  Gold nanoparticles are 
frequently synthesized via 
a traditional Brust-
Schiffrin two phase 
synthesis
25
.  However, this 
synthesis can be modified 
into a simple one pot 
aqueous synthesis.  In 
brief, Au
3+
 ions are 
reduced in the presence of 
thiol ligand of interest 
with sodium borohydride to yield gold 
nanoparticles, stabilized by an organothiol shell
26
 
(Figure 1.2).  Size can be controlled via percent 
methanol, ratio of thiol ligand to gold, ratio of 
reductant to gold, and temperature
27
.  Currently, a 
variety of sizes can be accessed, many between the 
1 and 100 nm range.  Not only is size tunability 
available in synthetic routes of gold nanoparticles, 
but monodispersity is also under synthetic control.  
There are currently mass spectrometry data or x-ray crystallography data for Au-25
28
, Au-38
29
, 
 
Figure 1.1.  Pymol images of gold nanoparticles.  A. Rendering of 
Au58 with “staple” structure of ligands on the gold surface.  B. 
Pymol image of 2.0 nm gold nanoparticle.  In orange, gold atoms.  
In yellow, sulfur atoms of ligands attached to the gold core. 
B A 
 
Figure 1.2. TEM image of 2.0 nm 
diameter p-mercaptobenzoic acid coated 
gold nanoparticles. 
20 nm
6 
Au-102
26
, and Au-144
30
, which correlate to ~1 nm (for Au-25 and Au-38), 1.5 nm, and 2 nm 
diameter gold core, respectively, making gold nanoparticles molecules, having true chemical 
formulas (i.e. [Au144(SC6H6CO2)52])
30
.    The passivating ligands can be exchanged in an 
associative type place exchange reaction, where incoming thiol ligands displace existing thiol 
ligands, resulting in a mixed thiol monolayer surrounding the gold nanoparticle
31
.  Furthermore, 
purification of the gold nanoparticles after each step can be accomplished with a sodium chloride 
and methanol treatment to precipitate the gold nanoparticles out of the solution
26
.  It has also 
been suggested that mixed thiol monolayers assembled onto the gold core can phase separate, 
producing a variety of ligand patterns on the surface.  These ligand patterns are hypothesized to 
create novel gold nanoparticle-biological structure interactions.  An example of this has been 
explored by Francesco Stellacci’s lab, where different phase separations on gold nanoparticles 
interact with mammalian cell membranes for internalization differently.  Striped phases of 
hydrophobic and anionic ligands displayed on gold nanoparticles were internalized within 
mammalian cells without endosomal entrapment, while random distributions of these ligands 
displayed on gold nanoparticles were internalized into endosomes
32.
  This is a nice example of 
how nanoscale structure can influence a biological interaction. 
   1.3 Applications of Gold Nanoparticles 
 With a wide variety of chemical functionalities available and the ability to create 
different ligand structures on gold nanoparticles, gold nanoparticles have been utilized in a 
variety of applications, such as sensors, catalysts, drug delivery vectors, and molecular 
diagnostics
33
.  Place exchange reactions allow for rapid diversification of the monolayer of the 
gold nanoparticles
31
.  Ligands of interest attach to the gold nanoparticle through a covalent gold-
7 
sulfur bond.  Gold nanoparticles can either be synthesized with this ligand of interest or the 
ligand can be introduced to the monolayer at a later stage, displacing the original functionality.    
 Novel characteristics of thiol ligands can be obtained through conjugation to gold 
nanoparticles.  Interested in exploiting this characteristic, the Jiang group in Beijing has created 
antimicrobial pyrimidine capped gold nanoparticles capable of inhibiting the growth of Gram- 
negative bacteria.  These nanoparticles were created though the reduction of gold ions in the 
presence of the pyrimidine thiol ligand of interest.  While the pyrimidine capping ligand is not 
antimicrobial by itself, gold nanoparticles coated with the pyrimidine ligand display 
antimicrobial activity against both lactam-susceptible and multidrug resistant strains of E. coli 
and P. aeruginosa
34, 35
.  These gold nanoparticles show the successful synthesis of gold 
nanoparticles with a specific biological activity.  Pyrimidine capped gold nanoparticles showed 
no cytotoxicity against human cells in culture at concentrations up to ten times those necessary 
for antimicrobial activity.  The authors conclude that further studies are necessary in order to 
probe the usefulness of this novel material in clinical use. 
 Gold nanoparticles have also been applied to drug delivery.  The Rotello group used gold 
nanoparticles for drug delivery by passivating gold nanoparticles with a targeting ligand of 
interest and a drug load of interest.  The targeting ligand of interest allows for specific 
localization of gold nanoparticles to a targeted site.  A variety of strategies can then be utilized to 
cause delivery of the drug load, such as glutathione mediated release, light mediated release, and 
noncovalent loading of drug molecules of interest
36
.  For example, glutathione mediated release 
allows for the displacement of the drug ligand of interest off of the gold surface with glutathione.  
Glutathione is a tripeptide of glutamic acid, cysteine, and glycine.  Cysteine contains a thiol 
functionality, allowing for attachment to the gold nanoparticle through a place exchange 
8 
reaction.  Furthermore, the mammalian intracellular concentration of glutathione is between 1 
and 10 mM, a sufficient concentration to cause exchange of the drug molecules from the gold 
nanoparticle,
37
 while extracellular concentrations of thiol ligands are <10 μM.  This 
concentration differential of glutathione allows for the selective delivery of a ligand of interest 
conjugated to gold nanoparticles into the intracellular space of cells.  Glutathione mediated 
release has been executed by the Nagasaki lab in vitro. The cytoplasmic delivery of siRNAs for 
gene silencing effects was demonstrated using gold nanoparticles functionalized with 
polyethylene glycol and siRNA, where release of siRNA from the surface of gold nanoparticles 
upon cellular internalization via glutathione mediated release was observed, with successful 
RNA interference activity
38
.  
   1.4 Our Approach for Identification of Antibiotic Gold Nanoparticles 
 We are interested in utilizing gold nanoparticles to address the multidrug resistance 
problem and probe the applicability of gold nanoparticles as an antibacterial material.  Although 
the general characteristics of gold nanoparticles mentioned before are applicable to our approach, 
the high chemical diversity that can be created on the surface of gold nanoparticles will be 
emphasized in this thesis. A mixed monolayer gold nanoparticle combinatorial library was 
created on ~2.0 nm diameter gold nanoparticles coated with p-mercaptobenzoic acid utilizing an 
initial thiol library of 10 thiols.   
 The large chemical diversity that can be achieved with gold nanoparticles in a 
combinatorial library is given by the mathematical formula: m!/(n!(m-n))!.  In this formula, m 
equals the number of thiols in the initial thiol library and n equals the number of thiols combined 
in the place exchange reaction.  This chemistry was taken advantage of by starting off with an 
initial thiol library of 10 compounds (Table 1.1).  Combination of these chemical functionalities 
9 
in random combinations of three on gold nanoparticles created a gold nanoparticle conjugate 
library of 120.  This is easily scalable, for example, if the initial thiol library is 100 thiol 
compounds, mixed in combinations of three on gold nanoparticles, then a library of 161, 700 
gold nanoparticle conjugates can be created, and if the same 100 thiol compound library was 
mixed in combinations of four on gold nanoparticles, then a gold nanoparticle conjugate library 
of 3, 921, 225 can be created. 
 A 120 member gold nanoparticle 
conjugate combinatorial library was created.  
Nanoparticle conjugates were then screened 
for growth inhibiting activity against a 
variety of different strains of bacteria.  
Differential growth inhibitory activity was 
observed to be dependent on the chemical 
functionalities attached to the gold surface.  
   1.5 Summary 
 In summary, multidrug resistance in 
bacteria is a serious problem facing global 
healthcare.  With the emergence of 
increasingly resistant strains of bacteria and 
the lack of emergence of new classes of antibiotics, a new method to antibiotic drug discovery is 
in high demand.  In contrast to small molecule drugs that have been traditionally used in 
antibiotic drug discovery, many researchers are now turning to alternate materials.  The hope of 
this is to gain a better understanding of the mechanisms of antibiotic resistance to allow for 
Thiol Characteristic 
3-Nitrobenzyl mercaptan Hydrophobic 
3-methyl-1-butanethiol Hydrophobic 
4-mercaptophenol Antimicrobial 
4-aminothiophenol Hydrophobic 
Glutathione Water soluble 
Cysteamine Amino acid 
structure 
Thioglucose Transporters 
3-mercapto-1-
propanesulfonic acid 
Water soluble 
2-diethylaminoethane thiol  Hydrophobic 
N-(methyl) 
mercaptoacetamide 
Hydrophobic 
Table 1.1.  Properties of selected thiols. 
10 
intelligent engineering of novel antibiotics.  Presented in this thesis is a combinatorial 
nanoparticle conjugate library created on ~2.0 nm diameter gold nanoparticles coated with p-
mercaptobenzoic acid.  A 120 member gold nanoparticle library was formed by mixing an initial 
thiol library of 10 in random combinations of three on gold nanoparticles.  Library creation was 
followed up by screening of this library against different strains of bacteria in order to identify 
gold nanoparticle conjugates capable of bacterial growth inhibition.  The most active 
nanoparticle conjugate designated LAL-32, displayed 99.9% growth inhibitory activity against 
E. coli at a concentration of 250 nM.  This nanoparticle conjugate contained the chemical 
functionalities glutathione, cysteamine, 3-mercapto-1-propane sulfonate, and p-mercaptobenzoic 
acid on the surface of gold nanoparticles and showed a moderate delay on the onset of resistance 
in E. coli.  Furthermore, this nanoparticle conjugate was observed to have a therapeutic index of 
400, indicating selective activity of gold nanoparticle conjugates toward growth inhibition of 
bacteria over general membrane disruption.   
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Chapter 2.  Identification of Antibiotics Using Small Molecule Variable Ligand Display on 
Gold Nanoparticles 
 
   2. 1 Introduction 
 
 In the past decade, gold nanoparticles have emerged as an important and versatile 
material for diagnosing and treating human disease
1-4
.  In disease diagnostics, the remarkable 
light extinction properties of gold nanoparticle probes have enabled rapid assays for both 
oligonucleotide and protein disease markers. These assays generally offer greater simplicity, 
selectivity, and sensitivity compared to conventional methods; indeed a gold nanoparticle-based 
test for prostate specific antigen reportedly provides a 10
6
-fold improvement over the standard 
ELISA method
3
.  In addition, several novel cancer treatment strategies that exploit gold 
nanoparticles as thermal ablators or drug delivery vectors are in clinical trials
5
.    
 We have hypothesized that gold nanoparticles may possess a number of attributes that 
make them useful drug candidates as opposed to drug carriers. For instance, gold nanoparticles 
are now accessible in a range of well defined sizes from ca. 1.0 nm to 10 nm
6-8
.  Moreover, the 
1.0 nm, 1.5 nm, and 2.0 nm diameter gold nanoparticles described recently are true molecules 
that have been characterized as being perfectly size monodisperse with exact chemical formulas 
as determined by X-ray crystallography or mass spectrometry ([Au25(SCH2CH2Ph18)]
7
, 
[Au102(S(CH2)6CO2H)27]
6
, and [Au144(SC6H4COOH)60]
9
, respectively). Methods for synthesizing 
these materials are easily reproduced and yield water-soluble compounds that are isolable as 
powders and scalable to multi-gram quantities. Gold nanoparticles also lend themselves to what 
amounts to an inorganic analogue of “click” chemistry in organic synthesis10.  Using thiol 
exchange reactions
11
, combinations of two or more chemically distinct ligands can be attached to 
a single particle to create multivalent and multifunctional systems. The ability to rapidly 
14 
assemble mixed thiol monolayers on a nanoscale platform provides a powerful tool that can be 
used to tune particle binding affinity to a biological target
12, 13
, and control cellular 
internalization
14, 15
 and sub-cellular localization
16
. The potential benefits of gold nanoparticle 
therapeutics were demonstrated recently in our labs by transforming a weak CCR5 binding small 
molecule, which by itself was biologically inactive, into a multivalent gold conjugate that 
effectively inhibited HIV-1 fusion to peripheral blood mononuclear cells (PMBCs) in vitro
17
. 
 The biological activity of ligand-coated gold nanoparticles in the prevention of HIV-1 
entry suggests that known, weak binding or perhaps even resistance-compromised small 
molecule drugs may be transformed into potent therapeutics via conjugation to gold 
nanoparticles. We were also interested in determining whether completely new biologically 
active compounds could be discovered using ligand-coated gold nanoparticles. Specifically, 
could we identify nanoparticle formulations whose biological activity was dictated by a specific 
combination of ligands displayed on the surface of the particle? In addressing this question we 
have exploited simple 1-pot multi-ligand exchange reactions to generate a library of ligand-
coated ~2.0 nm diameter gold nanoparticles that were then screened for antibiotic activity.  The 
amount of diversity that can be obtained by this system is given by this equation: m!/[n!(m-n)!], 
where n is the number of different ligands that are combined on the nanoparticle surface and m is 
the total number of ligands available. Herein, we demonstrate that mixed ligand-coated gold 
nanoparticles can be generated rapidly and screened to identify specific ligand sets that confer 
antibiotic activity. The results suggest that this type of variable small molecule ligand display on 
gold nanoparticle scaffolds may be a rapid and straightforward method for identifying new 
conjugates with biological activity.  
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   2.2 Results and Discussion 
 
Synthesis of the Library 
 
 The library of 120 nanoparticle conjugates (Table 2.1) was assembled by first 
synthesizing ~2.0 nm diameter gold nanoparticles capped with p-mercaptobenzoic acid 
(pMBA)
6
.  The ten thiols shown in Figure 2.1 were chosen as a representative library of 
molecules containing H-bond donor/acceptor and hydrophilic/hydrophobic properties. These 
ligands were incubated with gold nanoparticles in combinations of three (at 1:1:1 molar ratios), 
purified by salt/methanol precipitation, and members of the resulting library were screened for 
Figure 2.1. Illustration of the assembly of a library of mixed monolayer-coated gold 
nanoparticles and thiol ligands used to construct the library. 
16 
antibiotic activity against Escherichia coli (E. coli), a representative Gram-negative strain of 
bacteria and Staphylococcus aureus (S. aureus), a representative Gram-positive strain of bacteria. 
 
Table 2.1. List of Nanoparticle Conjugates Synthesized. 
17 
 
 
18 
Minimal Inhibitory Concentration Assays 
 
 Each nanoparticle formulation was initially screened for bacterial growth inhibition 
against E. coli at 50 μM and against S. aureus at 25 μM under standard broth dilution conditions 
followed by colony count analysis.  These initial screens revealed that activity of the 
nanoparticle conjugates depended upon the combination of thiols exchanged onto pMBA-coated 
gold nanoparticles while the base pMBA-coated gold nanoparticles themselves had no inhibitory 
effects on E. coli growth (< 0.5 log growth inhibition) and minimal effects on S. aureus growth 
(ca. l log growth inhibition). Nanoparticle conjugates from the initial screen that showed >90% 
growth inhibition were chosen for further analysis. The analysis was conducted by incubating 
cultures of bacteria with 
varying concentrations 
(50 nM to 50 μM) of 
nanoparticles in order to 
determine minimal 
inhibitory concentrations 
(MIC). For E. coli, 
nanoparticle conjugates 
19, 20, 30, and 83 (Table 
2.2) displayed the highest 
decrease in growth, with 
conjugate 20 (thiols 5, 6, 
and 8) yielding 99.9% 
growth inhibition at 250 
Table 2.2. Percent growth inhibition of E. coli by mixed ligand-
coated gold nanoparticles. Each conjugate was modified with 
pMBA and the thiols indicated.  All nanoparticle conjugates 
were synthesized on pMBA-capped gold nanoparticles.  Results 
were determined from triplicate assays. 
 
E. coli 
Conjugate 
Number  
Thiols % Inhibition Concentration (μM) 
20 5, 6, 8 99.9 0.25 
19 5, 6, 7 99.5 0.5 
30 1, 5, 6  99.9 5.0 
83 6,8, 9 99.9 0.5 
20a 6 40 0.5 
20b 5, 8 20 0.5 
20c 5, 6 90 0.5 
20d 6, 8 99.9 0.5 
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Table 2.3. Percent growth inhibition of S. aureus by mixed  
ligand-coated gold nanoparticles created on pMBA gold 
nanoparticles.  Results reported from triplicate determinations. 
S. aureus  
Conjugate 
Number 
Thiols % Inhibition Concentration (μM) 
28 1, 5, 8 99.9 25 
50 1, 5, 7 99.9 25 
56 1, 7, 8 99.5 25 
6 1, 2, 8 99.9 10 
50A 1,5 99.9 20 
 
nM.  The nanoparticles shown in Table 2.3 displayed the highest decrease in growth of S. aureus, 
with conjugate 6 yielding 99.9% growth inhibition at 10 µM.  Nanoparticle conjugates listed in 
Table 2.3 were also tested against methicillin resistant S. aureus. All conjugates were as active 
against MRSA as they were 
toward MSSA except 
conjugate 56, which showed 
only 99.0% growth inhibition 
at 50 µM.  
TEM of Gold Nanoparticles 
 
 The initial ~2.0 nm 
diameter pMBA coated gold 
nanoparticles were subjected 
to TEM and particle counting 
analyses (Figure 2.2).  From these studies, the average diameter of gold nanoparticles was 
determined to be 2.2 nm ± 0.4 nm.  Gold nanoparticle conjugate 20 was also analyzed by TEM 
and particle counting analyses (Figure 2.3).  The exchanged and purified gold nanoparticle 
conjugates were determined to be 2.4 nm ± 0.6 nm.  The overall average diameter of gold 
nanoparticle conjugate 20 did not change significantly, between the starting gold nanoparticle 
material and post place exchange reaction, while the dispersity did increase significantly after the 
place exchange reaction.  The ~2.0 nm diameter pMBA gold nanoparticles are similar to the 
particles characterized by mass spectroscopy by Wong et al.  The proposed molecular formula is 
Au230(SR)87 for these gold nanocrystals
19
. 
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Figure 2.2. TEM image of pMBA coated gold nanoparticles and particle diameter 
histogram pre-place exchange reaction. 
21 
 
 
Figure 2.3.  TEM image and particle diameter histogram of gold nanoparticles post-
place exchange reaction to create nanoparticle conjugate 20. 
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Free Thiol Analysis 
 
 The inhibitory activities of the individual, unconjugated thiols from gold nanoparticles 
were then assessed.  For nanoparticle conjugate 20 against E. coli, individual thiols 5 and 8 had 
no inhibitory effects towards E. coli growth at concentrations up to 2 mM (<20%). Thiol 6 
showed 90% inhibition at 1 mM and 99.9% inhibition at 2 mM.  In order for thiol 6 alone to be 
responsible for the inhibitory effects of conjugate 20, however, would require that 8,000 
molecules of thiol 6 were conjugated to the nanoparticle. This scenario is unlikely given that 
these particles can only accommodate about 87 thiol ligands. The possibility that combinations 
of the free thiols in solution could be responsible for the activity of conjugate 20 was also 
considered. Solution mixtures of thiols 5, 6, and 8 were examined, but showed only 90% 
inhibition of E. coli when each thiol was present in the broth at a concentration of 1 mM.  These 
data further support the notion that biologically inactive small-molecule ligands can be 
transformed into potent anti-viral/bacterial agents via conjugation to gold nanoparticles. 
 Given the observation that thiol 6 had some biological activity, we investigated whether 
the activity of conjugate 20 was due solely to the presence of thiol 6 on the surface of gold 
nanoparticles, perhaps due a multivalent effect that could dramatically increase the activity of the 
corresponding free thiol. This was tested by preparing pMBA-gold nanoparticles modified with 
thiol 6 alone (e.g., absence of thiols 5 and 8; denoted conjugate 20a in Table 2.2). These 
conjugates displayed only 40% growth inhibition of E. coli at 0.5 μM, a 0.2 log inhibition vs. the 
3 log inhibition (99.9%) of conjugate 20. Gold nanoparticles prepared with the identical 
concentrations of thiols 5 and 8 used to prepare the active conjugate 20 were also screened for 
activity.  These nanoparticles (20b) were significantly less active than conjugate 20, yielding 
only a 0.1 log growth inhibition (20%) at 0.5 μM.  Nanoparticles prepared with thiols 5 and 6 
23 
(20c), were also less active than conjugate 20, showing 90% inhibition at 0.5 μM. Finally, 
nanoparticles prepared with a mixed monolayer of thiols 6 and 8 (20d) displayed a comparable 
activity as conjugate 20, yielding 99.9% growth inhibition at a concentration of 500 nM.  It thus 
appears that the activity of conjugate 20 was due to the specific combination of thiols 6 and 8 on 
the nanoparticle. 
 The inhibitory activities of the individual, unconjugated thiols against S. aureus were 
then determined. Thiols 2, 5, 6, 8, 9, and 10 showed little to no inhibition of MSSA growth at 
concentrations as high as 2 mM (<0.4 log decrease).  Thiols 3 and 4 were potent growth 
inhibitors, which is not surprising since phenols and anilines are known antiseptics. It was also 
found that thiol 7 showed inhibitory activity of ca. 1 log at 2 mM. However, for this thiol alone 
to be responsible for the activity of nanoparticles 50 and 56 would require that nearly the entire 
monolayer of gold nanoparticles were covered with thiol 7, an unlikely scenario given that these 
nanoparticles can only accommodate about 87 ligands total and the amount of thiol 7 input into 
the place exchange reaction was less than this.  Thiol 1 could not be screened in solution due to 
poor solubility in the broth used. No inhibition was observed, however, on agar containing 500 
µM thiol 1 and 10% DMSO.  
 Various combinations of the free thiol monomers were then incubated with S. aureus. 
Surprisingly, binary mixtures of 50 µM pMBA and 50 µM thiol 1 or 150 µM pMBA and 150 
µM thiol 2 showed 99.9% MSSA growth inhibition. The activity of conjugates containing 
pMBA and thiols 1 or 2 is thus independent of their attachment to the nanoparticle; however, 
conjugation of thiol 1 to the nanoparticle has the advantage of converting it into a water-soluble 
conjugate. 
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Infrared Spectroscopy 
 
 To determine that the thiols utilized in place exchange reactions are actually attached to 
the surface of gold nanoparticles, infrared spectroscopy (IR) and ion-mobility mass spectrometry 
(IM-MS) were employed.  IM-MS was only utilized to confirm the presence of each thiol on the 
growth inhibiting E. coli conjugate 20, while IR was utilized for both E. coli growth inhibiting 
nanoparticle conjugates and S. aureus growth inhibiting nanoparticle conjugates. For nanopaticle 
conjugate 20, characteristic vibrations for thiols 5, 8, and pMBA were observed by IR (Figure 
2.4). Thiol 6 was not detected, either because it was not present in sufficient quantities to detect 
by IR or did not have vibrations that could be assigned unambiguously given the other thiols 
Figure 2.4.  IR spectra of nanoparticle conjugate 20, pMBA coated gold nanoparticles, and 
thiols 5 and 8. 
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present. IM-MS
20, 21
 detected the presence of all four thiols with an average coverage per 
nanoparticle for thiols 5, 6, 8, and pMBA of 38%, 32%, 17%, and 13% coverage, respectively 
(Table 2.4).   
 IR was also utilized 
to confirm the presence of 
thiols on S. aureus growth 
inhibiting conjugates 6, 28, 
and 50 (Figure 2.5).  
Characteristic vibrations 
for thiols 1 and 8 were 
observed for conjugate 6, and thiols 1 and 5 for conjugates 28 and 50.  Thiols 2, 8, and 7 were 
not detected in conjugates 6, 28, and 50, respectively, likely because they were not present in 
sufficient quantities to detect by IR or did not have vibrations that could be assigned 
unambiguously given the other thiols present.  
   2.3 Conclusions 
 
 Nanoscale systems including DNA aptamers, antibodies, proteins, and inorganic 
nanoparticles such as the gold particles described herein are attractive as therapeutics in part 
because of their tunable valencies, blood circulation times, and biodistribution profiles. In 
addition, nanoscale therapeutics are often adept at disrupting protein-protein interactions that can 
drive disease pathogenesis. In contrast, small molecule therapeutics typically rely on a single 
high-affinity contact to a disease target and have difficulty blocking protein-protein interactions. 
A significant advantage of small molecule drugs, however, is the ease with which large chemical 
Table 2.4. IM-MS data for gold nanoparticle conjugate 20.  % 
abundances determined from duplicate measurements. 
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and structural diversity can be manufactured and screened for biological activity. It has thus been 
proposed that methods capable of blending the properties of nanoscale systems with the chemical 
diversity of small molecules will lead to the discovery of superior therapeutic agents
22
.  
 In conclusion, we have shown that a library of small molecule ligand-coated gold 
nanoparticle conjugates may be generated rapidly via 1-pot thiol exchange reactions. The 
nanoparticle conjugates were prepared at room temperature in aqueous solution and purified 
using a simple aqueous salt/methanol precipitation and resuspension procedure. Considering 
solely the number of commercially available thiols (>200), there is potential to access significant 
Figure 2.5. IR spectra of active nanoparticle conjugates 6, 28, and 50 confirms the 
formation of mixed thiol monolayers. The * indicates a representative band for pMBA-Au 
nanoparticle conjugates (pMBA-AuNP). The ^, §, and £ correspond to vibrations unique 
to 3-(nitrobenzyl)mercaptan, glutathione, and 3-mercapto-1-propane sulfonate, 
respectively, as determined from spectra of the free thiols. 
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chemical and structural diversity with this approach.  While the aqueous solubility of the 
resulting nanoparticle conjugates may in some cases be low (as experienced with many of the 
compounds in our initial 120-member library), this can be overcome by simply tuning the molar 
ratios of the ligands during the exchange reaction or by combining thiols with low aqueous 
solubility with highly water soluble thiols. The library investigated here revealed differential 
activity toward the inhibition of E. coli growth, with one conjugate displaying 99.9% growth 
inhibition at 0.5 μM. The same differential activity was observed against S. aureus and 
methicillin resistant S. aureus, with one conjugate displaying 99.9% growth inhibition at 10 µM.  
Activity appears to depend upon both the display of ligands on the nanoparticle surface and on 
the specific combination of ligands displayed on the gold nanoparticle for E. coli, while 
combinations of thiol 1 and pMBA were sufficient for S. aureus growth inhibition.  Active gold 
nanoparticle conjugates did not overlap between the strains, except for nanoparticle conjugate 
30.  However, the activity of this nanoparticle conjugate against the growth of E. coli is 
hypothesized to be due to the presence of thiol 6, while activity against the growth of S. aureus is 
hypothesized to be due to the presence of thiol 1 and pMBA on the surface of gold nanoparticles.  
Whether the bacterial growth inhibition observed for these conjugates is due to efficient 
internalization, nanoparticle aggregation inside of the cells, or enhanced binding to a 
biomolecule target located in the cell membrane or inside of the cell is currently not known.  As 
a comparison we note that the minimum inhibitory concentrations of vancomycin, ciprofloxacin, 
and cefixime against S. aureus are ca. 0.7 µM, 1.5 µM, and 17 µM, respectively; thus 
nanoparticle formulations can be rapidly identified from simple thiol building blocks that are 
comparable to conventional antibiotics with respect to in vitro bacterial growth inhibition. 
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   2.4 Future Directions 
 
 With the potent growth inhibitory activity of gold nanoparticle conjugates 20 and 83 
against E. coli, further insights into the mode of action of these antimicrobial nanoparticles are 
necessary.  For example, determination of toxicity is necessary in order to determine whether or 
not these gold nanoparticles are general membrane disruptors or are specific for antimicrobial 
activity.  Furthermore, with the development of multidrug resistance in bacterial species a 
continuous threat to global health care, determination of the rate at which E. coli develops 
resistance against these gold nanoparticle conjugates will be assayed. 
 
The authors would like to thank The Bill and Melinda Gates Foundation for funding and Dr. 
Kellen Harkness and Professor David Cliffel for performing the IM-MS measurements. 
Thank you to Keith Maier for help with most of the experiments conducted in this chapter. 
Many thanks to Dr. Carly Carter and Jesse Hartman for TEM analysis and generation of size 
distribution histograms.  
   2.5 Experimental Methods 
 
Synthesis of 2.0 nm gold nanoparticles 
 
 Two nanometer diameter [Au144(SC6H4COOH)60] gold nanoparticles were synthesized as 
previously described
1
.  In short, a solution of 11.1 mM HAuCl4 (SigmaAldrich), 37.8 mM p-
mercaptobenzoic acid (p-MBA) (TCI-America), 178 mM NaOH in 55.6 % (v/v) aqueous 
methanol was prepared and allowed to equilibrate for 24 hours with constant stirring. Fifty 
milliliters of this solution (0.556 mmoles of Au
3+
) were diluted to a final Au
3+
 concentration of 
0.48 mM with the addition of 260 mL methanol and 740 mL water.  The Au
3+
 was reduced with 
the addition of 10 mL of 0.25 M NaBH4 (SigmaAlrich). The final methanol concentration was 
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adjusted to 24.8 % with the addition of 100 mL of water.  The reduction of gold was allowed to 
proceed for 48 hours at room temperature with constant stirring.  Gold nanoparticles were 
precipitated with the addition of 68 mmoles of NaCl and 500 mL of methanol (final methanol 
concentration of 47 % v/v) followed by centrifugation at 3200 RCF for five minutes. The 
precipitated nanoparticles were reconstituted in water. The concentration was measured by UV-
visible spectroscopy, using the ε510 nm of 409, 440 M-1cm-1.  Further, it was noted that the 
source of reagents for this synthesis is important to the preparation.  Ensuring that reagents were 
not stored with other chemicals that could react or contaminate them was also critical. 
Place exchange reactions 
 
 One pot place exchange reactions were conducted with the addition of 740 μM total thiol 
added in 1:1:1 molar ratio to 7.4 μM gold nanoparticles in 20 mM sodium phosphate buffer, pH 
9.5.  Reactions were placed on a plate shaker and agitated for 24 hours at room temperature.  The 
exchange product was harvested through the addition of 40 mmoles of NaCl and a volume of 
methanol equal to that of phosphate buffer and added salt. Reactions were centrifuged at 3200 
RCF for 30-60 minutes.  Precipitated nanoparticles were resuspended and precipitated with the 
addition of NaCl and methanol two times to wash out excess unreacted thiol.  Particles were 
allowed to dry to completion overnight at room temperature and resuspended in water and 
washed with water over a 10K MWCO centricon filter to remove excess salt and thiol. 
 In order to optimize exchange reactions, the molar feed ratios of thiols added into the 
reaction can be altered.  For example, as nanoparticle compounds 28 and 50 were relatively 
insoluble after place exchange reactions in aqueous media and had low yields, the amount of (3-
nitrobenzyl)mercaptan was reduced to ⅔ the original feed.   
30 
 For E. coli growth inhibition gold nanoparticle conjugates, molar feed ratios of 33:1 thiol 
ligand:gold were utilized for thiols 5, 7, 8, 9, and 10, while a molar feed ratio of 46:1 was 
utilized for thiol 6. 
Bacterial growth inhibition assays 
 
 Inoculation of E. coli or S. aureus into 3 mL of Mueller-Hinton broth (Fisher) was carried 
out by touching the top of 4 well isolated colonies of E. coli (ATCC 25922) or S. aureus (ATCC 
29213) from a Mueller-Hinton agar (Fisher) plate with an inoculation loop.  The culture was 
allowed to grow at 37 °C, 225 rpm for 4 hours after which it was diluted to 1 x 10
6
 CFU/ml in 
Mueller-Hinton broth.  Equal volumes of diluted inoculum and nanoparticle sample (adjusted to 
the correct assay concentration in Mueller-Hinton broth) were mixed to make the final inoculum 
concentration 5 x 10
5
 CFU/ml.  Samples were incubated at 37 °C, 225 rpm for 18 hours.  End 
points were determined by colony counting on Mueller-Hinton agar after dilution of each sample 
in PBS and incubation of the plates at 37 °C for 24 hours.  Minimal inhibitory assays were 
conducted by incubation of bacteria with various concentrations of gold nanoparticles (i.e. E. coli 
was incubated with 0.125, 0.25, 0.5, 1, 2, 5, 10, 25, and 50 μM gold nanoparticle conjugate in 
order to identify minimal inhibitory concentrations).  
Infrared spectroscopy 
 
 Nanoparticle samples were reconstituted and washed of contaminants over a 30K 
MWCO centricon filter with water.  Samples were then spotted onto potassium bromide Real 
Crystal IR cards (International Crystal Laboratories) in their appropriate solvent and allowed to 
dry.  IR analysis was carried out on a Thermo Nicolet Avatar 360 FT-IR E.S.P. 
 
 
31 
   2. 6 References 
 
[1.] Goluch, E. D.; Nam, J. M.; Georganopoulou, D. G.; Chiesl, T. N.; Shaikh, K. A.; Ryu, K. S.; 
Barron, A. E.; Mirkin, C. A.; Liu, C.  Lab on A Chip.  2006, 6, 1293-99. 
 
[2.] Rosi, N. L.; Giljohann, D. A.; Thaxton, C. S.; Lytton-Jean, A. K.; Han, M. S.; Mirkin, C. A. 
Science.  2006, 312, 1027-30. 
 
[3.] Thaxton, C. S., Georganopoulou, D. G., Mirkin, C. A. Clinica Chimica Acta. 2006, 363, 
120–126. 
 
[4.] West, J. L; Halas, N. J.  Curr. Opin. in Biotechnology.  2000, 11, 215-17. 
 
[5.] Farma, J. M.; Puhlmann, M.; Soriano, P. A.; Cox, D.; Paciotti, G. F.; Tamarkin, L.; 
Alexander, H. R.  International Journal of Cancer.  2007, 120, 2474-80. 
 
[6.] Jadzinsky, P. D.; Calero, G.; Ackerson, C. J.; Bushnell, D. A.; Kornberg, R. D.  Science.  
2007, 318, 430-33. 
 
[7.] Heaven, M. W.; Dass, A.; White, P. S.; Holt, K. M.; Murray, R. W.  J. Am. Chem. Soc.  
2008, 130, 3754. 
 
[8.] Ackerson, C. J.; Jadzinsky, P. D.; Jensen, G. J.; Kornberg, R. D.  J. Am. Chem. Soc.  2006, 
128, 2635-40. 
 
[9.] Lopez-Acevedo, O.; Akola, J.; Whetten, R. L.; Gronbeck, H.; Hakkinen, H. J.  Phys. Chem. 
C.  2009, 113, 5035-38. 
 
[10.] Finn, M. G.; Kolb, H. C.; Fokin, V. V.; Sharpless, K. B.  Progress in Chemistry.  2008, 20, 
1-4. 
 
[11.] Ingram, R. S.; Hostetler, M. J.; Murray, R. W.  J.Am.Chem.Soc.  1997, 119, 9175. 
 
[12.] Boal, A. K.; Rotello, V. M.  J. Am. Chem. Soc.  2000, 122, 734. 
 
[13.] Ghosh, P. S.; Han, G.; Erdogan, B.; Rosado, O.; Rotello, V. M.  Journal of Peptide Science.  
2008, 14, 134. 
 
[14.] Liu, Y. L.; Shipton, M. K.; Ryan, J.; Kaufman, E. D.; Franzen, S.; Feldheim, D. L.  Anal. 
Chem.  2007, 79, 2221. 
32 
 
[15.] Verma, A.; Uzun, O.; Hu, Y. H.; Hu, Y.; Han, H. S.; Watson, N.; Chen, S. L.; Irvine, D. J.; 
Stellacci, F.  Nature Materials.  2008, 7, 588. 
 
[16.] Tkachenko, A. G.; Xie, H.; Coleman, D.; Glomm, W.; Ryan, J.; Anderson, M. F.; Franzen, 
S.; Feldheim, D. L.  J. Am. Chem. Soc.  2003, 125, 4700. 
 
[17.] Bowman, M. C.; Ballard, T. E.; Ackerson, C. J.; Feldheim, D. L.; Margolis, D. M.; 
Melander, C.  J. Am. Chem. Soc.  2008, 130, 6896. 
 
[18.] Turos, E.; Revell, K. D.; Ramaraju, P.; Gergeres, D. A.; Greenhalgh, K.; Young, A.; 
Sathyanarayan, N.; Dickey, S.; Lim, D.; Alhamadsheh, M. M.; Reynolds, K.  Bioorganic & 
Medicinal Chemistry.  2008, 16, 6501. 
 
[19.] Wong, A. O., Heinecke, C. L., Simone, A. R., Whetten, R. L., Ackerson, C. J. Nanoscale. 
DOI:10.1039/c2nr30259d. 
 
[20.] Harkness, K. M.; Fenn, L. S.; Cliffel, D. E.; J. A. McLean. Anal. Chem. 2010, 82, 3061.  
 
[21.] Harkness, K. M.; McLean, J. A.; Cliffel, D. E..  Anal. Chem. submitted for publication. 
 
[22.] C. Rader; S. C. Sinha; M. Popkov.; R. A. Lerner.; C. F. Barbas, Proceedings of the 
National Academy of Sciences of the United States of America.  2003, 100 (9), 5396. 
 
 
 
 
 
 
 
 
 
 
 
 
 
33 
Chapter 3. Preliminary Mode of Action Studies of Antimicrobial Gold Nanoparticles 
Accessed Through Small Molecule Variable Ligand Display Against E. coli     
 
   3.1 Introduction 
 The emergence of resistance to multiple antimicrobial agents in pathogenic bacteria has 
become a significant global public health threat. Drug-resistant bacterial infections cause 
considerable patient mortality and morbidity, and rising antibiotic resistance is seriously 
threatening the vast medical advancements made possible by antibiotics over the past 70 years. 
Without developing innovative approaches to combat these multidrug resistant pathogens, many 
fields of medicine will be severely affected, including surgery, premature infant care, cancer 
chemotherapy, care of the critically ill, and transplantation medicine, all of which are feasible 
only with the existence of effective antibiotic therapy. This situation is so dire that the world 
health organization has identified multidrug resistant (MDR) bacteria as one of the top three 
threats to human health
1
, while the infectious disease society has issued a call to action from the 
biomedical community to deal with the MDR bacterial threat.
2
 
 In response to this unmet medical need, our labs and others have been exploring synthetic 
ligand-coated gold nanoparticles (1 nm – 5 nm diameter) as therapeutics for the treatment of 
viral and bacterial diseases.
3-6
 Gold nanoparticle therapeutics have a number of unique properties 
that are distinct from small molecule therapeutics including tunable valency and in vivo 
circulation half life, diameters that are slightly larger than drug efflux pumps, and the ability to 
disrupt protein-protein interactions.
7-11
 These characteristics suggest that gold nanoparticles may 
have the potential to access new pathogen targets and delay the onset of drug resistance.  
 Another important characteristic of gold nanoparticles is the ease with which they can be 
synthesized and modified with one or more chemically distinct thiol ligands.
12-14
 We showed 
previously that this thiol modification chemistry enables the rapid construction of combinatorial 
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libraries of small molecule/gold nanoparticle conjugates that may be screened for biological 
activity.
4,5
 In this “small molecule variable ligand display” (SMVLD) approach, mixtures of thiol 
ligands (typically three or more) are combined with gold nanoparticles in one pot to create mixed 
ligand monolayer/gold nanoparticle conjugates that are rapidly isolated via simple precipitation 
for subsequent biological screening purposes.  
   3.2. Results and Discussion 
 The utility of the SMVLD approach was demonstrated by using a set of ten commercially 
available thiols to assemble a pilot library of 120 distinct gold particle conjugates on ca. 2.0 nm 
diameter p-mercaptobenzoic acid (pMBA) coated gold nanoparticles (Figure 3.1, compounds 1-
10). This library was then screened against the Gram-negative bacterium Escherichia coli to 
identify formulations capable of inhibiting the growth of E. coli by 99.9% (MIC99.9).  Differential 
growth inhibition was observed based on the thiol ligands attached to the gold nanoparticle 
surface.  Several different nanoparticle formulations in the library were found to be potent 
growth inhibitors of E. coli (Table 3.1) (The starting pMBA-capped nanoparticles had no 
inhibitory activity at the highest concentration tested, 50 μM).  Further investigation of the 
monolayer of one of the most active nanoparticle conjugates, LAL-32, revealed that not only 
were all four ligands attached to the surface of the nanoparticle, but attachment of ligands to the 
surface of the gold nanoparticle was required for activity.  
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Figure 3.1. Thiol ligands used in the the assembly of a library of mixed monolayer-coated 
gold nanoparticles. 
 
Table 3.1. List of Nanoparticle conjugates capable of inhibiting the growth of E. coli.  Values 
reported are the results of averaging of 10 or more measurements. 
Previous 
Designation 
Conjugate 
Number Thiol A Thiol B Thiol C MIC99.9, μM 
20 LAL-32 5 6 8 0.25 
83 LAL-33 6 8 9 0.5 
20f LAL-42 6 8  0.5 
 LAL-52 5 6 11 0.25 
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Ligand Display Index 
 The activity of the most potent formulation, designated LAL-32, along with the activity 
of two other lead formulations, LAL-33 and LAL-42 are outlined in Table 3.1.  In addition to 
ligand-dependent bacterial growth inhibition, we observed that the ligands must be displayed on 
the nanoparticle surface to be active.
15
  LAL-32 contains an estimated average mixed monolayer 
composition of 11 pMBAs, 33 thiol 5s, 28 thiol 6s, and 15 thiol 8s (based off of previous ion 
mobility mass spectrometry data and a proposed molecular formula of Au230(SR)87
5
), and 
inhibited E. coli bacterial growth with a MIC99.9 of 250 nM.
15
  When used as individual free 
thiols, the MIC99.9 of thiols 6 and 9 were 2 mM and 0.4 mM, respectively, while the MIC99.9 of 
thiols 5 and 8 were >2 mM.  Combinations of ligands in solution showed no synergy. To 
quantify this effect we define the Ligand Display Index (LDI) as the ratio of the MIC99.9 of a 
mixture of the free ligands to the MIC99.9 of the ligands bound to the nanoparticle. The LDI of 
LAL-32 is ca. 290, indicating that on a per ligand basis nanoparticles modified with thiols 5, 6, 
and 8 are 290x more active than the corresponding free ligands.
15
  The absolute number of each 
ligand/nanoparticle was estimated with the proposed  chemical formula for the pMBA coated 2.0 
nm diameter gold nanoparticle starting material, of Au230(SR)87
5
, which had a diameter of (2.2 
nm ± 0.4 nm).  The average percentage values for the ligands on LAL-32 were previously 
determined by IM-MS by Kellen Harkness in David Cliffel’s lab at Vanderbilt University as 
13% pMBA, 38% thiol 5, 32% thiol 6, and 17% thiol 8
15
.  The percentages obtained by IM-MS 
for ligand coverage combined with a hypothesized average of 87 ligands/particle were used to 
estimate absolute values for ligand coverage of LAL-32.  The MIC of the free ligands combined 
in solution in the same feed ratio as that obtained for LAL-32 was 6.3 mM total thiol 
concentration (0.79 mM pMBA, 2.4 mM thiol 5, 2 mM thiol 6, and 1.1 mM thiol 8).  The MIC 
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of the ligands bound to the nanoparticles was 21.75 μM, which is the MIC of the nanoparticles 
(250 nM) multiplied by the estimated value of 87 ligands/particle.  6.3 mM total free thiol 
compared to 21.75 μM thiol on nanoparticles yields the LDI of ca. 290. 
Nanoscale Stucture-Activity Relationship Studies  
 Given the overlapping ligand sets of LAL-32, -33, and -42, the first question we 
addressed was whether there was a strict requirement of these ligands for antibacterial activity.  
Using a subsequent nanoscale structure-activity relationship study (NSAR) in which the ligand 
diversity of LAL-32 was increased by combining thiols 5, 6, and 8 with five new thiols (11-
amino-undecane thiol (thiol 14), 11-mercapto-1-undecane sulfonate (thiol 15), 3-mercapto-
N,N,N-trimethylpropan-1-aminium (thiol 12), 6-amino-2-(((5-mercapto-3-
oxopentyl)oxy)amino)hexanoic acid (thiolated lysine) (thiol 13), and 3-(1H-imidazol-4-yl)-2-
(((5-mercapto-3-oxopentyl)oxy)amino)propanoic acid (thiolated histidine) (thiol 11)).  Presented 
here are further characterizations of the active gold nanoparticle conjugates.   
 3-mercapto-N,N,N-trimethylpropan-1-aminium 
 Since thiol 6 is present in all formulations of active nanoparticle conjugates and thiol 6 
displays 99.9% growth inhibitory activity against E. coli as a free thiol in solution at a 
concentration of 2 mM, structure-activity studies were carried out on this thiol.  Cysteamine 
(thiol 6) was replaced with 3-mercapto-N,N,N-trimethylpropan-1-aminium (Thiol 12)  (Figure 
3.1) in place exchange reactions to result in a new subset of gold nanoparticle conjugates.  These 
studies allowed for probing of the importance of the cationic amine for antimicrobial activity.  In 
each of these place exchange reactions, the same feed ratio (or higher) of thiol 12 was utilized 
compared to the original thiol 6.  These nanoparticle conjugates were then screened against E. 
coli for growth inhibitory activity.  No activity of the resultant gold nanoparticle conjugates 
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Table 3.2.  List of Nanoparticle conjugates with the quaternary 
ammonium thiol ligand (thiol 12).  MIC values determined from 
triplicate analyses. 
Conjugate 
Number Thiol A Thiol B Thiol C MIC, μM 
20g 12   na 
20h 5 12  na 
20i 8 12  na 
20j 5 8 12 na 
20k 9 12  na 
20l 8 9 12 na 
 
against E. coli was observed (Table 3.2).  While both ligands contain a cationic amine group, the 
lack of activity when the quaternary ammonium group is utilized suggests that charge is not the 
only property governing activity.  
 Longer Linker 
Length Ligands 
 In order to assess any 
dependence on the distance 
between thiol chemical 
functionality and gold 
nanoparticle on 
antimicrobial activity of gold nanoparticle conjugates, 11-amino-undecane thiol (thiol 14) and 
11-mercapto-1-undecane sulfonate (thiol 15) were utilized in place exchange reactions in place 
of thiols 6 and 8, respectively.  All combinations of one, two, and three thiol place exchange 
reactions (for example, for LAL-32, all combinations that can be conducted with the thiol ligands 
attached to the surface are thiol 5 alone, thiol 6 alone, thiol 8 alone, thiols 5 and 6, thiols 5 and 8, 
thiols 6 and 8, and thiols 5, 6, and 8, all created on pMBA-gold nanoparticles) were conducted 
with these thiols and subsequent nanoparticle conjugates were assayed against E. coli to 
determine MIC99.9 values.  No resultant gold nanoparticle conjugates had growth inhibitory 
activity and good aqueous stability.  For thiol 14, the feed ratio had to be dropped to 9:1 molar 
ratio of thiol:gold (original feed ratio of 46:1 for thiol 6) to synthesize water-soluble 
nanoparticles. Feed ratios above this resulted in insoluble gold nanoparticle conjugates.  The lack 
of activity of the resultant gold nanoparticle conjugates could be due to the low feed ratio of 
chemical functionality, resulting in a low amount of chemical ligand displayed on the surface of 
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the gold nanoparticle or the ineffectiveness of the longer linker length thiol.  However, at this 
time, it is not possible to make a definitive conclusion on the reason for the lack of activity of the 
resultant gold nanoparticle conjugates.  Similar issues were observed when thiol 15 was utilized 
in place exchange reactions.  While the feed ratio did not need to be altered significantly (22:1 
molar ratio compared to 33:1 molar ratio of ligand to gold for thiol 15 and thiol 8, respectively), 
many resultant gold nanoparticles had limited solubility in aqueous solution.  Furthermore, most 
of the resulting gold nanoparticle conjugates did not have any growth inhibitory activity against 
E. coli.  The exception to this was a gold nanoparticle conjugate resulting from a place exchange 
reaction with thiol 5 (33:1 molar ratio ligand:gold), thiol 6 (46:1 molar ratio), and thiol 15 (22:1 
molar ratio), which displayed an MIC99.9 of 500 nM.  However, when the concentration exceeded 
5 μM in biological media, precipitation of gold nanoparticle conjugate was observed.  
Furthermore, as the combination of thiols 5 and 6 on gold nanoparticles was shown to be 
effective in growth inhibition of E. coli (90% growth inhibition at 500 nM), the effectiveness of 
this nanoparticle conjugate was not surprising, although, the increase in activity was interesting.  
Again, clear conclusions on the role of increasing the distance between the chemical 
functionality and gold nanoparticle cannot be made at this time.  In general, the longer linker 
length thiols had dramatic solubility issues in biological media and inactivity in inhibiting the 
growth of E. coli.  Possibly, polyethylene glycol units can be introduced into the carbon chain to 
increase the distance between chemical functionality and gold nanoparticle surface without 
sacrificing aqueous solubility in the future. 
 Modified Amino Acid Ligands 
 Antimicrobial cationic peptides are well documented as part of the innate immune system 
for defense against pathogens.  The positive charge that antimicrobial peptides possess allows for 
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Table 3.3. List of Nanoparticle conjugates with amino acid thiol 
ligands (thiols 11 and 13).  MIC values determined from triplicate 
analyses. 
Conjugate 
Number Thiol A Thiol B Thiol C MIC, μM 
AA1 5 13  na 
AA2 5 11  na 
AA3 6 13  na 
AA4 6 11  na 
AA5 8 13  na 
AA6 8 11  na 
AA7 9 13  na 
AA8 9 11  na 
AA9 12 13  na 
AA10 11 12  na 
AA11 5 6 13 0.25 
LAL-52 5 6 11 0.25 
AA13 5 12 13 na 
AA14 5 11 12 na 
AA15 6 8 13 0.5 
AA16 6 8 11 0.5 
AA17 8 12 13 na 
AA18 8 11 12 na 
AA19 5 8 13 na 
AA20 5 8 11 na 
AA21 6 9 13 0.5 
AA22 6 9 11 0.5 
AA23 9 12 13 na 
AA24 9 11 12 na 
AA25 8 9 13 na 
AA26 8 9 11 na 
 
interaction with bacterial membranes, which are negatively charged.  Through analysis of the 
sequences of known antimicrobial peptides, three amino acids are commonly observed, namely 
arginine, lysine and histidine.  In hopes of taking advantage of some of these properties, histidine 
(thiol 11) and lysine (thiol 13) were modified with a short polyethylene glycol linker attached to 
a monothiol functionality and introduced into the initial thiol library (Figure 3.1).  All 
combinations of one, two, and three thiol place exchange reactions were conducted with these 
thiol ligands (and thiols 5, 6, 
8, and 9) onto pMBA-gold 
nanoparticles.  No activity 
was noted when either of the 
amino acid thiol ligands was 
displayed on pMBA-gold 
nanoparticles alone.  
Activity was only obtained 
for certain ternary thiol 
combinations, where one of 
the thiols utilized in the 
place exchange reaction was 
an amino acid functionality 
and another was cysteamine 
(Table 3.3).  In depth 
analysis, such as NMR, of 
the monolayer is needed in 
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order to confirm the presence of amino acid functionalities on the surface of gold nanoparticles 
and for quantification of the monolayer.  The impact of the amino acid functionalities on growth 
inhibitory activity was then assessed by utilizing the resultant gold nanoparticle conjugates in 
minimal inhibitory assays, resistance assays, blood hemolysis assays, and MTT assays, alongside 
active members of the original nanoparticle conjugate library.  An additional nanoparticle 
formulation, LAL-52, that is equipotent to LAL-32 was identified from this screen.  
 In general, the NSAR studies revealed the necessity of thiol 6 on the surface of gold 
nanoparticles for growth inhibitory activity.  Experiments conducted with the quaternary 
ammonium thiol 12 revealed that activity does not merely arise from the positively charged 
amine group.  Also of interest is determination of whether thiol 6 is sufficient for activity if a 
water soluble gold nanoparticle conjugate were to be formed with this thiol ligand.  It has been 
proposed that when thiol 6 is conjugated to gold nanoparticles with pMBA, a limited amount of 
thiol 6 can be attached, resulting in decreased activity compared to LAL-32.  However, if more 
thiol 6 can be conjugated to the surface of gold nanoparticles with aqueous solubility, will this 
gold nanoparticle conjugate display activity?  Further studies on active gold nanoparticle 
conjugates resulting from NSAR studies will allow for determination of the properties of 
different chemical functionalities that enhance biological activity. 
Broad Spectrum Activity of Nanoparticle Conjugates 
 LAL-32 and LAL-52 were further assayed against a variety of bacterial strains to 
determine if growth inhibitory activity is specific to E. coli or if the nanoparticle conjugates are 
broad spectrum.  To address this question, LAL-52 was assayed against Gram-negative MDR 
strains of P. aeruginosa (clinical Isolates UNC A and UNC B from cystic fibrosis patients), A. 
baumannii (ATCC BAA-1605), an NDM-1 producing strain of K. pneumoniae (ATCC BAA-
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Table 3.4.  MIC activity of Nanoparticle conjugates against various strains of bacteria 
 
K. 
pneumoniae 
ATCC         
BAA-2146 
A. 
baumannii 
ATCC         
BAA-1605 
S. 
aureus  
MRSA                  
ATCC                
BAA-44 
P.  
aeruginosa 
P.  
aeruginosa 
E. coli                   
 ATCC                  
BAA-199,  
BAA-200 
 
ATCC 
29213 
UNC A UNC B 
LAL-32 0.625 >10 >10 >10 N/A N/A N/A 
LAL-52 0.625 >10 >10 >10 >10 0.625 0.156 
*MIC values are displayed in μM.  P. aeruginosa UNC A and UNC B are clinical isolate strains. 
2146), and two MDR E. coli strains (ATCC BAA-199 and BAA-200).  Activity was observed 
for K. pneumoniae (MIC99.9 = 625 nM), one of the clinical strains of P. aeruginosa, UNC B 
(MIC99.9 = 625 nM), and the MDR E. coli strains (MIC99.9 = 156 nM), but no activity was 
observed against the other strains of bacteria tested.  The Gram-positive strains S. aureus and 
methicillin resistant S. aureus (MRSA) were also tested; however gold nanoparticle conjugates 
were not active against either of these strains (Table 3.4).  Initial studies also indicated that LAL-
33 and nanoparticle conjugates containing thiols 6, 8, and 9 (Table 3.5, indicated with asterisk) 
were effective against Mycobacterium smegmatis at a concentration of 2.5 μM in vitro.  Further 
investigations are necessary in order to characterize the mode of action of gold nanoparticle 
conjugates against M. smegmatis and determine a formulation capable of inhibiting the growth of 
other Mycobacterial species, such as TB.  Together, these data imply that the gold nanoparticle 
conjugates are not specific to E. coli alone, but are not broad spectrum. 
Minimal Bactericidal Concentrations 
 To determine whether these nanoparticle conjugates are bactericidal or bacteriostatic 
against E. coli, minimum bactericidal concentration assays were conducted.  This was achieved 
by incubating E. coli in the presence of 1X, 2X, 4X, 8X, and 16X the minimal inhibitory 
concentration of gold nanoparticle conjugates to obtain the concentration of nanoparticle 
conjugate necessary for causing >99.9% growth inhibition of the original E. coli inoculum.  
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From these studies, minimal bactericidal concentrations were not accessed, as no decrease to the 
original inoculum was observed.  Therefore, gold nanoparticle conjugates are bacteriostatic in 
activity. 
Resistance Assays 
 In order to determine how quickly E. coli develops resistance against active nanoparticle 
conjugates, resistance assays were performed.  Serial passages of E. coli in the presence of sub-
inhibitory concentrations of gold nanoparticle conjugates were carried out for up to 50 days.  The 
Table 3.5.  Thiol titrations utilized to make novel gold nanoparticle conjugates utilizing the 
thiols in LAL-33.  MIC99.9 data are against E. coli. * indicates nanoparticle conjugates 
capable of inhibiting the growth of M. smegmatis (preliminary data).  MIC values were 
determined in triplicate. 
LAL-33 Molar feed ratio  
Reaction # Thiol 6 Thiol 8 Thiol 9 MIC99.9, μM 
1 16.2 16.2 16.2 >2  
2 16.2 33.8 16.2 2 
3 33.8 16.2 16.2 >2 
4 16.2 33.8 33.8 >2 
5 16.2 16.2 33.8 >2 
6 33.8 16.2 33.8 >2 
7 33.8 33.8 16.2 0.5 
8 16.2 45.9 16.2 2 
9 16.2 16.2 45.9 >2 
10 45.9 16.2 16.2 >2 
11 16.2 45.9 45.9 >2 
12 45.9 16.2 45.9 >2 
13* 45.9 45.9 16.2 0.25 
14 33.8 33.8 33.8 0.5 
15 33.8 45.9 33.8 0.5 
16 33.8 33.8 45.9 >2 
17* 45.9 33.8 33.8 0.5 
18 33.8 45.9 45.9 0.5 
19* 45.9 45.9 33.8 1 
20* 45.9 45.9 45.9 0.5 
21 45.9 33.8 45.9 2 
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time necessary for E. coli to develop resistance against nanoparticle conjugates was dependent 
on thiol functionalities attached to the gold nanoparticles.  While E. coli developed resistance 
against most of the nanoparticle conjugates tested within 30 days of passaging, which resulted in 
greater than a 10 fold increase in the minimal inhibitory concentration, one nanoparticle 
conjugate, LAL-32 was capable of displaying growth inhibitory activity after 50 days of 
passaging.  After this period of time, the minimal inhibitory concentration increased to 5 fold the 
original minimal inhibitory concentration (Figure 3.2).  As a comparison, E. coli developed 
resistance to the commercial antibiotic chloramphenicol within 2 days of passaging (MIC 
increase from 12 μM to 99 μM).  This indicates that tuning of the rate of resistance development 
Figure 3.2. Evolution of resistance in E. coli to Nanoparticle conjugates.  
    represents LAL-32,   represents LAL-33,   represents LAL-42,   represents LAL-52.  
Endpoints at 10 μM indicate the highest concentration of nanoparticle conjugates tested, 
with no MIC99.9 achieved.  MIC values at various time-points were observed in duplicate. 
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in E. coli can be controlled with the different chemical functionalities attached to the surface of 
gold nanoparticle conjugates.  
Size Dispersity Effects of Gold Nanoparticle Conjugates 
 It was previously noted that the size dispersity of gold nanoparticles changes during the 
place exchange reaction (see Chapter 2).  In an effort to quantify this effect, TEM analysis was 
performed with a slight change in the particle diameter of 2.2 ± 0.4 nm to 2.4 ± 0.6 nm for LAL-
32 noted.  No significant changes in the absorption spectrum, such as broadening of the plasmon 
resonance band between 510 and 520 nm were detected that would indicate a large change in 
size dispersity (Figure 3.3).  This agreed with the finding that the smaller diameter gold 
nanoparticles isolated from the post-place exchange reactions (~1.0 nm) is a small fraction 
Figure 3.3. UV-visible spectra of aqueous solutions containing pMBA-gold nanoparticles 
(Blue) and LAL-32 (Red). 
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(<10%).  The same observation was true for the larger diameter gold nanoparticle fractions (~4.0 
nm).  The increase in size dispersity was an interesting observation as determination of the sizes 
of gold nanoparticle conjugates that are responsible for antimicrobial action can be conducted.  
For example, are the smaller gold nanoparticles (~1.0 nm in diameter) or the larger (~4.0 nm in 
diameter) gold nanoparticles the antibiotic fraction; or are all of the sizes seen via TEM in the 
post-exchange gold nanoparticles contributing to the antibiotic effects observed?   
 Investigations on the size dispersity observed in exchanged gold nanoparticles as a 
function of time are also underway.  Place exchange reactions were carried out for a longer 
duration of time, up to one month, to determine if the size dispersity increases further with time 
or if it remains unchanged.  More specifically, does enrichment of the ~1.0 nm diameter gold 
nanoparticle fraction occur with increased length of the place exchange reaction?  This would 
allow for selective screening of the ~1.0 nm diameter gold nanoparticle conjugates for 
antimicrobial activity.  Initial findings indicated that the size dispersity did increase with 
increasing amounts of time that place exchange reactions were allowed to proceed.  Broadening 
of the plasmon band via absorbance spectrum was noted over time, which indicated an increase 
in the dispersity of gold nanoparticles.  Further investigations are needed in order to quantify this 
effect, such as TEM analysis and fractionation of the different sizes of gold nanoparticles created 
in place exchange reactions.  Once the different sizes are separated, subsequent screening for 
antibacterial activity of each size fraction can be conducted to determine if antibacterial activity 
of gold nanoparticle conjugates is size dependent. 
Titration of Thiols 
 The molar feed ratios of thiols utilized in the place exchange reactions can also be 
modified in order to generate novel gold nanoparticle conjugates.  This was of interest as 
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optimizing of the gold nanoparticle conjugates for antimicrobial activity, rate of resistance 
evolution, and toxic effects might be controllable in the place exchange reaction.  One of the 
benefits associated with SMVLD is that activity of nanoparticle conjugates was dependent on the 
feed ratios of the thiols utilized in the place exchange reactions (Tables 3.5 and 3.6).  Therefore, 
one question that arises is whether resistance-compromised nanoparticle formulations can be 
reactivated by simply modifying their feed ratios during the ligand-exchange step.  For example, 
the synthesis of LAL-33 was the result of a place exchange reaction utilizing thiol:gold molar 
ratios of 33:1 for thiols 8 and 9 and 46:1 for thiol 6 (Reaction 17, Table 3.5).  While E. coli did 
become resistance compromised with this specific formulation after about 10 days (MIC99.9 > 10 
Table 3.6.  Thiol titrations utilized to make novel gold nanoparticle conjugates utilizing the 
thiols in LAL-32.  MIC99.9 data are against E. coli determined in triplicate. 
LAL-32 Molar feed ratio  
Reaction # Thiol 5 Thiol 6 Thiol 8 MIC99.9, μM 
1 16.2 16.2 16.2 >2  
2 16.2 33.8 16.2 0.5 
3 33.8 16.2 16.2 >2 
4 16.2 33.8 33.8 1 
5 16.2 16.2 33.8 >2 
6 33.8 16.2 33.8 >2 
7 33.8 33.8 16.2 0.5 
8 16.2 45.9 16.2 >2 
9 16.2 16.2 45.9 >2 
10 45.9 16.2 16.2 >2 
11 16.2 45.9 45.9 0.5 
12 45.9 16.2 45.9 >2 
13 45.9 45.9 16.2 0.5 
14 33.8 33.8 33.8 0.5 
15 33.8 45.9 33.8 0.25 
16 33.8 33.8 45.9 0.5 
17 45.9 33.8 33.8 0.5 
18 33.8 45.9 45.9 0.25 
19 45.9 45.9 33.8 0.5 
20 45.9 45.9 45.9 0.5 
21 45.9 33.8 45.9 0.5 
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μM), the growth of this resistant E. coli population could still be inhibited (MIC99.9 = 2 μM) by a 
nanoparticle conjugate synthesized with higher feed ratios of the same thiol ligands (46:1 thiol 
:gold molar ratio of each thiol 6, 8, and 9) (Reaction 20, Table 3.5).  While there were observable 
improvements on the MIC99.9 of LAL-33 with the different place exchange reactions, no 
improvement to the original 250 nM MIC99.9 of LAL-32 was noted.  It was determined that 
resistance developed faster with LAL-32 reaction 14 compared to the original nanoparticle 
conjugate (Reaction 15, Table 3.6), which was proposed to be due to fewer thiol ligands attached 
to the surface of the gold nanoparticle conjugates due to the lower feed ratios of thiols input into 
the place exchange reaction.  Together, these findings indicate that not only can the addition of 
thiol functionalities to the initial thiol library increase diversity of resultant gold nanoparticle 
conjugates, but simple tuning of the molar feed ratios of existing thiol functionalities can also 
result in gold nanoparticle conjugates with different biological activity. 
Effects of Biological Media on Growth Inhibitory Activity  
 It has been hypothesized that gold nanoparticle conjugates can lose activity in biological 
media due to the thiol functionalities often found in these solutions exchanging onto gold 
nanoparticles.  This would result in loss of active chemical functionality on the nanoparticle 
conjugate.  Determination of activity of gold nanoparticle conjugates after incubation in 
biological media was necessary (for these purposes, calcium free Dulbecco’s Modified Eagle 
Medium supplemented with 10% fetal bovine serum was utilized).  As can be seen in Figure 3.4, 
a 24 hour incubation at 37 °C of gold nanoparticle conjugates in this medium prior to MIC assay 
being conducted had little effect (either no change to the MIC, or a change to the original MIC 
within double the original value) on the MIC of gold nanoparticle conjugates determined.                             
 Blood hemolysis and MTT assays 
49 
Table 3.7. Hemolytic and Therapeutic Indices of Nanoparticle conjugates 
Nanoparticle 
Conjugate 
Thiols 
Hemolysis 
IC50, μM  
MIC99.9, 
μM 
Hemolytic 
Index* 
Toxicity 
IC50, μM 
Therapeutic 
Index* 
LAL-32 5, 6, 8 100 0.25 400 100 400 
LAL-42 6, 8 100 0.5 200 50 100 
LAL-33 6, 8, 9 50 0.5 100 20 40 
* The hemolytic index is defined as the IC50/MIC99.9, while the therapeutic index is defined as the 
IC50/MIC99.9.  Indices were determined with both MTT and apoptosis and necrosis assays.  MTT 
assays were run in triplicate and apoptosis and necrosis assays were run in duplicate, with toxicity 
observed to be associated with the induction of apoptosis and necrosis in HepG2 cells.  
  
Figure 3.4.  MIC determination of gold nanoparticle conjugates after a 24 hour incubation in 
biological media.  Blue bars are MIC of gold nanoparticle conjugates incubated in water.  
Red bars are MIC of gold nanoparticle conjugates incubated in Dulbecco’s Modified Eagle 
Medium without calcium and supplemented with 10% fetal bovine serum for 24 hours at 
37°C.  MIC values determined in duplicate. 
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 Blood hemolysis assays against defibrinated sheep’s blood cells were then conducted to 
determine the toxicity of gold nanoparticle conjugates against mammalian blood cells.  
Incubating different nanoparticle conjugates in the presence of defibrinated sheep’s blood cells, 
yielded blood hemolytic indices.  Hemolysis was dependent upon thiol functionalities attached to 
the gold nanoparticles.  All nanoparticle conjugates tested had some selectivity for growth 
inhibition of E. coli over lysis of mammalian cell membranes.  The best hemolytic index 
observed was 400, which was recorded for LAL-32 (Table 3.7).   
 MTT assays were then conducted with different nanoparticle conjugates against Human 
embryonic kidney cells (HEK293) and human liver cells (Hep G2/2.2.1) to determine if 
nanoparticle conjugates interfere with cell proliferation.  From these assays, therapeutic indices 
were obtained, which indicate if nanoparticle conjugates have selectivity of growth inhibition of 
E. coli over interfering with cellular proliferation of human cells.  Again, all nanoparticle 
conjugates tested had activity that was specific for E. coli growth inhibition and did not interfere 
with cell proliferation of the two human cell lines tested at similar concentrations.  The highest 
therapeutic index obtained was 400, which corresponded to LAL-32 (Table 3.7).  Together, this 
data implies that LAL-32 has good specificity for inhibiting the growth of E. coli over general 
cellular proliferation disruption, which indicates that these nanoparticle conjugates are not 
generally cytotoxic, non-specific cell membrane disruptors. 
Membrane permeability 
 Membrane permeability studies were then carried out with LAL-32 against E. coli to 
determine whether or not the mode of action of nanoparticle conjugates against growth inhibition 
of E. coli is to interfere with the cellular membrane through electrostatic interactions.  No 
membrane disruption was observed.  Furthermore, the specificity of the primary amine chemical 
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functionality in cysteamine over cationic charge was previously determined necessary for 
activity of gold nanoparticle conjugates.  Together, these data indicate that a more complex mode 
of action than poking holes in the cellular membrane of bacteria cells is responsible for activity. 
   3.3 Conclusions 
 The results presented here show that the mixed ligand monolayer/gold nanoparticle 
conjugates isolated via the SMVLD screening method are potent bacteriostatic agents against 
multiple MDR Gram-negative strains of E. coli and K. pneumoniae.  Importantly, the conjugates 
are not generally cytotoxic, non-specific cell membrane disruptors. They are therefore not 
“nuisance compounds” that frequently emerge from whole cell small-molecule drug screens, 
which act equally on both bacterial and mammalian cells.
16
 Further NSAR studies conducted on 
active gold nanoparticle conjugates identified a new active nanoparticle conjugate LAL-52, 
containing a histidine amino acid chemical functionality.  A more in depth analysis of this 
nanoparticle conjugate is necessary to determine the effects of the addition of histidine into the 
monolayer of gold nanoparticle conjugates. When the effects of longer linker length thiols were 
investigated, the long alkane thiol linker resulted in insolubility of resultant gold nanoparticle 
conjugates in aqueous media.  Polyethylene glycol can be investigated as a water soluble linker 
in future analysis.   
 It was also discovered that these gold nanoparticle conjugates exhibited significantly 
delayed evolution of resistance compared to the small molecule antibiotic chloramphenicol. 
Moreover, different resistance rates were observed for nanoparticles with seemingly subtle 
differences in ligand composition.  LAL-32 and LAL-42, for instance, differed by only the 
deletion of thiol 5 from LAL-32 to LAL-42 yet, despite having similar initial MIC99.9 values, the 
rate at which resistance developed changed from >50 days for LAL-32 to 4 days for LAL-42. A 
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detailed genetic screen will likely provide a deeper understanding of these preliminary findings, 
including the mode of action of the various nanoparticle formulations and the mechanisms by 
which bacteria evade these antibacterial particles.  Such studies are currently underway.  
 Another interesting characteristic of gold nanoparticle conjugates is the ability to tune the 
biological activity of gold nanoparticle conjugates by changing the feed ratio of thiols utilized in 
place exchange reactions.  This principle was utilized in order to show growth inhibition of a 
LAL-33 resistant E. coli population LAL-33 (Reaction 17, Table 3.5) with a gold nanoparticle 
conjugate synthesized with the same thiols, but in a higher molar feed ratios during place 
exchange reaction (Reaction 20, Table 3.5).  Furthermore, with different LAL-33 reactions 
(Table 3.5) capable of inhibiting the growth of M. smegmatis at 2.5 μM, tuning of the biological 
activity of gold nanoparticles during place exchange reactions, without the addition of novel 
chemical functionalities can be an important tool.  To conclude, irrespective of the specific mode 
of action, the low MIC99.9, high hemolytic and therapeutic indices, and slow onset of resistance 
observed for these gold nanoparticles suggest that they are potentially viable new candidates for 
the treatment of MDR Gram-negative bacteria. 
   3.4 Future Directions 
 The isolation of gold nanoparticle conjugates capable of inhibiting the growth of E. coli 
by 99.9% with some level of specificity toward bacterial growth inhibition over general 
membrane disruption, determination of in vivo toxicity is necessary.  The information gained 
from murine models would allow for further progression of the project.  For example, if toxicity 
occurred, then tuning of the monolayer via place exchange reactions can be conducted in order to 
tune pharmacokinetic properties, such as circulation lifetimes. 
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 Other mode of action studies are also of interest to identify specific cellular processes 
disrupted due to the presence of gold nanoparticle conjugate in bacterial cells.  For example, 
what effects are observed with different chemical functionalities attached to the surface of gold 
nanoparticles (i.e. histidine)?  Apoptosis and necrosis assays in Hep G2 human liver cells are 
currently underway to conclude if the toxic effects in mammalian cells due to gold nanoparticles 
are caused by the induction of apoptosis or necrosis.  Also, membrane potential assays in 
bacterial cells are underway to assess whether or not gold nanoparticle conjugates induce 
changes in the bacterial membrane potential.  Furthermore, during place exchange reactions, the 
size dispersity of gold nanoparticles was noted to change.  Current investigations are being 
conducted to determine if there is a time dependence between the duration of place exchange 
reaction and the size dipsersity obtained.  Other investigations could be conducted in order to 
determine the impact of the amount of thiol added to place exchange reactions on resultant size 
dispersity.  For example, is LAL-33 Reaction 20 (Table 3.5) active against resistant E. coli (to 
the original LAL-33) due to higher feed ratios allowing for more chemical functionalities to 
exchange onto the surface of gold nanoparticles or does the higher feed ratio of thiols in place 
exchange reaction select for a certain size that is more active that the whole population of gold 
nanoparticles created during the place exchange reaction to generate LAL-33?  Determination of 
the active size fractions that are created during these reactions will further our understanding of 
the mode of action of active gold nanoparticle conjugates.   
 Lastly, a quantitative method for evaluation of the monolayer of resultant gold 
nanoparticle conjugates is necessary to make comparisons between monolayers of different 
nanoparticle conjugates.  For example, when titrations of thiols are utilized, are more chemical 
functionalities actually exchanging onto the surface of gold nanoparticles when higher feed ratios 
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are utilized, are the different chemical functionalities utilized in NSAR studies exchanging onto 
the gold nanoparticles, and do thiol ligands exchange off in the presence of biological medias?  
All of these questions can be addressed with the ability to quantify the monolayer of gold 
nanoparticle conjugates.  NMR analyses as well as HPLC methods are being investigated to 
fulfill this need.   
 
Thank you to Theresa Nahreini for her assistance in cell culture experiments. 
   3.5 Experimental Methods 
Synthesis of gold nanoparticles 
p-mercaptobenzoic acid-capped gold nanoparticles (p-MBA-Au) were synthesized as 
previously described.
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 A solution of 11.1 mM HAuCl4 (SigmaAldrich), 37.8 mM p-
mercaptobenzoic acid (p-MBA) (TCI-America), 178 mM NaOH in 55.6 % (v/v) aqueous 
methanol was prepared and allowed to equilibrate for 24 hours with constant stirring. Fifty mL of 
this solution (0.556 mmoles of Au
3+
) were diluted to a final Au
3+ 
concentration of 0.48 mM with 
the addition of 260 mL methanol and 740 mL water.  The Au
3+ 
was reduced with the addition of 
10 mL of 0.25 M NaBH4 (SigmaAlrich). The final methanol concentration was adjusted to 
24.8% with the addition of 100 mL of water.  The reduction of gold was allowed to proceed for 
48 hours at room temperature with constant stirring.  Gold nanoparticles were precipitated with 
the addition of 68 mmoles of NaCl and 500 mL of methanol (final methanol concentration of 47 
% v/v) followed by centrifugation at 3200 RCF for five minutes. The precipitated nanoparticles 
were reconstituted in water. The concentration was measured by UV-visible spectroscopy, using 
the ε510 nm of 409, 440 M
-1
cm
-1
.  Further, it was noted that the source of reagents for this 
synthesis is important to the preparation.  Ensuring that reagents were not stored with other 
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chemicals that could react or contaminate them was also critical. Transmission electron 
microscopy (TEM) was used to determine the average size of the particles. 
Place exchange reactions 
One-pot place exchange reactions were conducted with 7.4 μM gold nanoparticles in 4 
mL of 20 mM pH 9.5 sodium phosphate buffer.  Feed ratios of thiols were modified to increase 
activity of the resultant nanoparticle conjugates and are as follows: thiols 5, 8, 9 were utilized in 
33X molar excess of gold nanoparticles, while thiols 6 and 12 were utilized at 46X molar excess 
of gold nanoparticles.  Thiol 11 was utilized in 18X molar excess of gold.  Stocks of thiols were 
20 mM in water, except for thiol 11, which was dissolved in DMSO.  Reactions were placed on a 
plate shaker and agitated for 24 hours at 19°C.  The exchange product was harvested through the 
addition of 40 mmoles of NaCl and a volume of methanol equal to that of phosphate buffer and 
added salt. Reactions were centrifuged at 3200 RCF for 30 minutes.  Precipitated nanoparticles 
were resuspended and precipitated with the addition of NaCl and methanol two times to remove 
excess unreacted thiol.  Particles were allowed to dry to completion overnight at room 
temperature and resuspended in water and washed with water over a 10K MWCO centricon filter 
to remove excess salt and thiol. TEM was used to determine the size of the exchange product 
LAL-32. The size distribution was observed to increase slightly, with particles ranging in size 
from ca. 1.3 nm to 2.7 nm (size standard deviation of 0.4 nm vs. 0.2 for pMBA-Au).  As the 
molar extinction coefficient for gold nanoparticles in this size regime does not change 
considerably (2.33 x 10
5
  L/mol
3
 cm and 1.29 x 10
6
 L/mol
3
 cm for 1.3 nm and 2.7 nm diameter 
gold nanoparticles).
17,18 
 The extinction coefficient reported above for 2.2 nm diameter particles 
was used to prepare solutions of LAL-32 for bacterial growth inhibition assays. UV-visible 
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spectroscopy confirmed that the major product in the synthesis of LAL-32 consisted of particles 
with similar visible light extinction characteristics to the starting pMBA-Au nanoparticles.  
Bacterial growth inhibition assays 
Inoculation of E. coli into 3 mL of Mueller-Hinton broth (Fisher) was carried out by 
touching the top of 4 well isolated colonies of E. coli (ATCC 25922) from a Mueller-Hinton agar 
(Fisher) plate with an inoculation loop.  The culture was allowed to grow at 37 °C, 225 rpm for 4 
hours after which it was diluted to 1 x 10
6
 CFU/ml in Mueller-Hinton broth.  Equal volumes of 
diluted inoculum and nanoparticle sample (adjusted to the correct assay concentration in 
Mueller-Hinton broth) were mixed to make the final inoculum concentration 5 x 10
5
 CFU/ml.  
Samples were incubated at 37 °C, 225 rpm for 18 hours.  End points were determined by colony 
counting on Mueller-Hinton agar after dilution of each sample in PBS and incubation of the 
plates at 37 °C for 24 hours.  Minimal inhibitory concentration values determined from 
incubation of E. coli in the presence of a range of concentrations of gold nanoparticle conjugates 
from 0.125 μM to 5 μM.  Values were determined in at least triplicate, with MIC values assessed 
via turbidity, with the same value resulting as the MIC with each assay. 
Mycobacterium smegmatis inhibition assays were conducted with ATCC 700084.  
Assays were carried out by touching the top of 4 well isolated colonies from a Middlebrook 
7H10 plate (BD) with an inoculation loop into Middlebrook 7H9 media supplemented with 
0.05% Tween 80 (to prevent clumping).  The culture was allowed to grow at 37 °C, 225 rpm 
overnight after which it was diluted to 1 x 10
6
 CFU/ml in Middlebrook 7H9 media supplemented 
with Tween 80.  Equal volumes of diluted inoculum and nanoparticle sample (adjusted to the 
correct assay concentration in Middlebrook 7H9 media supplemented with Tween 80) were 
mixed to make the final inoculum concentration 5 x 10
5
 CFU/ml.  Samples were incubated at 37 
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°C, 225 rpm for 2 days.  End points were determined by colony counting on Middlebrook 7H10 
agar after dilution of each sample in PBS and incubation of the plates at 37 °C for 3 days.  
Resistance assays 
 E. coli cells were passed up to 50 days in broth containing 60% the MIC value of 
nanoparticle conjugates.  Minimal inhibitory concentration screening at various time points 
occurred in order to monitor the MIC of various nanoparticle compounds.  Complete resistance 
of E. coli to nanoparticle conjugates was defined as a resultant MIC 10 times or greater the 
original MIC of nanoparticle conjugate.  MIC values were assessed as described above, with the 
same value resulting in duplicate for each time point. 
Hemolysis assays 
 Hemolysis assays were performed on mechanically difibrinated sheep blood (Hemostat 
Labs: DSB100).  1.5 mL of blood was placed into a microcentrifuge tube and centrifuged at 
10000 rpm for ten minutes.  The supernatant was removed and then the cells were resuspended 
with 1 mL of phosphate-buffered saline (PBS).  The suspension was centrifuged, the supernatant 
was removed and cells resuspended two more times.  The final cell suspension was then diluted 
tenfold.  Test compound solutions were made in PBS in small culture tubes and then added to 
aliquots of the tenfold suspension dilution.  PBS alone was used as a negative control and as a 
zero hemolysis marker whereas a 1% Triton X sample was used as a positive control and the 100 
% lysis marker.  Samples were then placed in an incubator at 37 °C while being shaken at 200 
rpm for 24 hours.  After one hour, the samples were transferred to microcentrifuge tubes and 
then centrifuged at 10000 rpm for ten minutes.  The resulting supernatant was diluted by a factor 
of 40 in distilled water.  The absorbance of the supernatant was measured with a UV 
spectrometer at a 540 nm wavelength.  Since the gold nanoparticle samples absorb readily at a 
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540 nm wavelength, each test sample was paired with an equal concentration of test compound 
blank in which the absorbance of was to be subtracted from that of the sample to determine the 
absorbance of possible red blood cell lysis.  Values were determined in triplicate. 
Cell culture 
 HEK293 cells (ATCC CRL-1573) were cultured in DMEM supplemented with 10% FBS 
and 1% pen/srep and incubated at 37 °C, 5% CO2 humidified.  HepG2/2.2.1 liver cells (ATCC 
CRL-11997) were cultured in 1:1 ratio of DMEM and Ham’s F12 media with 2.5 mM L-
glutamine, 15 mM HEPES, 0.5 mM sodium pyruvate and 1200 mg/L sodium bicarbonate, 
supplemented with 10% FBS, 0.4 mg/ml G418.  Incubation at 37 °C, 5% CO2 occurred.  The 
media was changed to calcium, pyruvate free DMEM supplemented with 10% FBS and 1% 
pen/strep for all nanoparticle assays. 
MTT assays 
 MTT assays (Biotium #30006) were carried out as indicated by manufacturer’s 
instructions.  Briefly, cells were seeded at 1 x 10
4
 cells/well in 96 well plates.  After 24 hours, 
nanoparticle compound was added to the cells and further incubation at 37 °C for 24 hours 
occurred.  Cells were then washed three times with media to remove excess nanoparticle and a 
final 100 μl of media was added to the cells.  Ten microliters of MTT assay reagent was then 
added to each well and incubation at 37 °C, 5% CO2 for 4 hours occurred.  The media was then 
removed and 200 μl of DMSO was added to the cells to dissolve the formazan crystal.  
Absorbance readings at 570 nm and 630 nm occurred and metabolic activity was calculated by 
subtracting the 630 nm reading from the 570 nm reading.  Values were determined in triplicate 
for each cell line. 
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Apoptosis and Necrosis Analysis 
 Apoptosis, necrosis, and healthy cell readings were carried out according to 
manufacturer’s instructions (Biotium #30018).  Briefly, cells were seeded at 1 x 104 cells/ml in 
appropriate media.  After 24 hours, nanoparticle compound was added to the cells and cells were 
further incubated for 24 hours at 37 °C, 5% CO2.  Cells were then washed two times with PBS 
and then trypsinized.  Cells were then centrifuged and resuspended at a concentration of 2-3 x 
10
6
 cells/ml in 1X binding buffer supplied with the kit.  One hundred microliter aliquots of cells 
were incubated with 5 μl of FITC-Annexin V and 5 μl of Ethidium homodimer III for 15 minutes 
at room temperature, in the dark.  Four hundred microliters of 1X binding buffer was then added 
to samples and sorted using FACS with excitation with a 488 nm laser and FITC and Texas Red 
filter sets. 
Membrane Permeabilization Assay 
 The BacLight assay (Invitrogen) was used to assess membrane permeability.  K. 
pneumonia (ATCC BAA-2146) was grown overnight in cation adjusted Mueller hinton broth at 
37 C, shaking.  The culture was diluted 1:40 in broth and grown to an optical density at 600 nm 
or ~1.0 (~4 hr growth).  The cultures were centrifuged at 10,000 g for 15 minutes and the cell 
pellet was washed once in sterile water, with a subsequent resuspension at 1/10
th
 of the original 
volume.  Further dilution 1:20 into water with test compound then occurred.  Suspensions were 
incubated at 37 C with shaking for 1 hour.  Samples were then centrifuged at 10,000 g for 10 
minutes, washed once with sterile water, and resuspended in water.  A 1:1 mixture of SYTO-9 
and propidium iodide was added to the suspension and mixed well.  One hundred microliters of 
the suspension was then added to each well of a 96 well plate and the plates were incubated in 
the dark for 15 minutes at room temperature.  Green fluorescence (SYTO-9) was read at 530 nm 
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and the red fluorescence (propidium iodide) was read at 645 nm (excitation wavelength 485 nm).  
The ratio of green to red fluorescence was expressed as a percentage of the control.  
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Chapter 4.  In Vivo Toxicity of Antibacterial Gold Nanoparticle Conjugate LAL-32 in 
Murine Models 
 
   4.1 Introduction 
 Multi-drug resistant bacteria are a world-wide problem.  Resistant strains of bacteria have 
been identified in every country surveyed by the World Health Organization
1,2
.  In parallel to 
small molecule antibiotic development, nano-scale therapeutics are being explored to address the 
resistance crisis.  Nanoparticles are one such material as they display many novel characteristics, 
such as optical properties
3
, that make them useful a wide variety of applications
4-6
, including 
therapeutics.  While most nanoparticles display unique pharmacokinetic properties due to size, 
shape, and passivating ligands, some generalities of nanoparticles in vivo have emerged.  For 
example, many nanoparticles in the 10-100 nm size range exhibit favorable in vivo clearance and 
biodistribution properties
7
, with nanoparticles greater than 10 nm capable of avoiding renal 
filtration and nanoparticles greater than 200 nm observed to be filtered by the liver and spleen in 
the reticuloendothelial system
8
.   
 Specifically, gold nanoparticles have been utilized in drug delivery applications with 
some preliminary success.  Gold nanoparticles have been employed in thermal ablation 
applications for tumor treatment in vivo.  The West and El-Sayed groups, to name a couple, have 
conducted studies on gold coated silica nanoshells
9, 10
.  Coupling of targeting ligands, such as 
EGFR onto the surface of the nanoshells
10
, which is overexpressed by many forms of cancer, 
allows nanoshells to be delivered to a specific, localized site.  Upon localization of the 
nanoshells to the tumor, irradiation with near infrared light, which also has good tissue 
penetration, specifically heats the nanoshells, causing destruction of tumor cells
9, 10
. 
 Further in vivo properties of gold nanoparticles have been explored by the Cliffel lab.  
His group has noted that while tiopronin coated gold nanoparticles ca 2.5 nm in diameter were 
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toxic above 20 μM in murine models, addition of 10% polyethylene glycol to the surface of gold 
nanoparticles relieved this toxicity
11
.  The effect of polyethylene glycol has previously been 
shown by others as well to increase circulation half-lives in vivo and prevent serum protein 
binding onto the surface of gold nanoparticles
12
.  This result highlights the ability to rapidly alter 
the monolayer of gold nanoparticles with a place exchange reaction to tune in vivo properties of 
the resultant gold nanoparticles. 
 Presented here are initial toxicity studies in murine models with a previously identified 
antibacterial gold nanoparticle conjugate, LAL-32.  This gold nanoparticle conjugate was 
isolated from a screen of 120 unique gold nanoparticle conjugates created on ~2.0 nm diameter 
p-mercaptobenzoic acid (pMBA) coated gold nanoparticles. The conjugates were tested against 
E. coli to identify gold nanoparticle conjugates capable of inhibiting bacterial growth.  LAL-32 
was capable of inhibiting the growth of E. coli with a minimal inhibitory concentration (MIC99.9) 
of 250 nM.  Furthermore, this gold nanoparticle conjugate displayed good initial selectivity for 
bacterial growth inhibition over general membrane disruption
13
. 
   4.2 Results and Discussion 
 LAL-32 in murine models 
 Gold nanoparticle conjugate LAL-32 was synthesized as previously described
13
.  LAL-32 
displays the thiols pMBA, glutathione (thiol 5), cysteamine (thiol 6), and 3-mercapto-1-propane 
sulfonate (thiol 8) on the surface of gold nanoparticles (Figure 4.1). LAL-32 was injected 
intraperitoneally into 15 BALBc/cAnNHsd mice at two concentrations, 10 and 60 μM each.  
LAL-32 induced significant distress in mice dosed with 60 μM shortly after injection and mice 
were euthanized 24 hours post-injection.  However, mice injected with 10 μM LAL-32 tolerated 
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Figure 4.1.  Thiol ligands utilized to synthesize 
LAL-32 and LAL-32P. 
the injection and in vivo circulation as well as biodistribution of gold nanoparticles was 
monitored up to 4 weeks post-injection. 
 Both sets of mice injected at the 
10 and 60 μM concentrations of LAL-32 
had renal clearance of gold 
nanoparticles.   Gold was present in both 
the urine (Figure 4.2) and blood (Figure 
4.3) immediately post-injection.  Mice 
injected with 10 μM LAL-32, 
concentrations of gold present in the 
urine decreased over time, with no gold 
detected after 24 hours, however, levels 
of gold were detected in the blood up to 
4 weeks post-injection.  Concentrations of gold present in the blood and urine decreased with 
time over 24 hours post-injection when mice were injected with 60 μM gold nanoparticles.  
Levels of gold were also detected in organs, namely, the liver, spleen, kidney, heart, and lung at 
24 hours post-injection for both the 10 μM and 60 μM (Figure 4.4) concentrations and at 2 and 4 
weeks post-injection for the 10 μM concentration (Figures 4.5 and 4.6).  Mice injected with 10 
μM LAL-32 had gold accumulation in the liver predominantly, with the next highest levels of 
gold detected in the kidney, spleen, lung, and heart, respectively after 24 hours.  This would 
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indicate liver and kidney filtration of gold nanoparticles.  Mice injected with 60 μM LAL-32 had 
  
 
 
Figure 4.2.  Gold levels detected in urine post-injection with 10 μM and 60 μM LAL-32.  
Error bars representative of the average gold detected in urine from 5 mice, with ICP-MS 
analysis conducted in duplicate for each sample. 
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Figure 4.3.  Levels of gold detected in the blood of mice post-injection with LAL-32 at 10 μM 
and 60 μM.  Error bars representative of the average gold detected in blood from 5 mice, with 
ICP-MS analysis conducted in duplicate for each sample. 
 
gold predominantly present in the lung and kidney 24 hours post-injection.  Gold was also 
detected in the liver, heart, and spleen at decreasing levels, respectively.  The slightly altered 
profile of gold in organs between the two dosage concentrations explains the toxicity observed in 
the mice injected with 60 μM LAL-32 as the high amounts of gold present in the kidneys at this 
concentration is known to be associated with renal failure.
14
  Obvious distress was noted in these 
mice due to this effect and mice were euthanized 24 hours post-injection.  Mice injected with 10 
μM LAL-32 had liver and kidney filtration of the gold nanoparticles after 24 hours, but did not 
display renal failure.  A similar trend in the biodistribution of gold in mice injected with 10 μM 
  
 
Figure 4.4.  Biodistribution of gold in various organs of mice after injection with LAL-32.  
Error bars representative of the average gold detected in each organ from 5 mice, with ICP-
MS analysis conducted in duplicate for each sample. 
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LAL-32 was observed after 2 and 4 weeks, with the most abundant levels of gold detected in the 
liver and spleen at both of these times (Figure 4.5 and 4.6).  This further indicates that LAL-32 
underwent filtration in the liver and spleen, most likely through the reticuloendothelial system. 
 
Figure 4.5. Biodistribution of gold in various organs after 2 weeks post-injection with 10 μM 
LAL-32.  Error bars representative of the average gold detected in various organs from 5 mice, 
with ICP-MS analysis conducted in duplicate for each sample. 
 
 LAL-32 with polyethylene glycol in murine models 
 In order to address the toxic effects of injecting mice with 60 μM LAL-32 and in hopes of 
improving the in vivo circulation of LAL-32 at both dosage concentrations in murine models, 
polyethylene glycol (thiol 16) was introduced into the monolayer of LAL-32 gold nanoparticles.  
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Polyethylene glycol has been previously noted to improve in vivo circulation lifetimes by 
 
preventing serum protein binding onto gold nanoparticles and to reduce in vivo toxicity of gold 
nanoparticles
12
.  A triethylene glycol functionality with an 11 carbon chain was attached to a 
thiol group for conjugation to the gold surface (thiol 16).  A similar longer length polyethylene 
glycol ((11-Mercaptoundecyl)tetra(ethylene glycol)) has been shown to yield favorable 
biodistribution and circulation effects on gold nanoparticles
14
.  Addition of polyethylene glycol 
occurred via place exchange reactions.  A titration of thiol 16 in place exchange reactions was 
carried out to determine the effect(s) of thiol 16 on the monolayer of gold nanoparticles (Table 
4.1).  Resultant nanoparticle conjugates were then screened for MICs. Antimicrobial properties 
of LAL-32 were not affected by addition of thiol 16 up to a 30:1 feed ratio (the highest feed ratio 
tested).  A 15:1 molar feed ratio of thiol 16:gold was selected for animal studies as these particles 
Figure 4.6. Biodistribution of gold in various organs 4 weeks post-injection with 10 μM 
LAL-32.  Error bars representative of the average gold detected in various organs from 5 
mice, with ICP-MS analysis conducted in duplicate for each sample. 
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provided a good yield (>75% the 
yield obtained when synthesizing 
LAL-32) in place exchange 
reactions and also maintained the 
250 nM MIC against E. coli.  This 
resultant gold nanoparticle 
conjugate was designated LAL-
32P. 
 LAL-32P was then injected 
intraperitoneally into mice at 10 
μM and 60 μM as previously done 
for LAL-32.  Initial observations 
indicate that toxic effects of gold nanoparticles with thiol 16 were reduced.  The mice injected 
with 60 μM LAL-32P did not show the same distress as mice injected with the original LAL-32 
at 60 μM.  As a result, animals were not euthanized after 24 hours.  Gold levels in the blood and 
urine were monitored after injection of LAL-32P.  Gold levels were also measured in the organs 
of mice, specifically, the lungs, heart, liver, spleen, and kidneys.  The mode of clearance of LAL-
32P will be determined to asses if other favorable biodistribution and clearance effects of gold 
nanoparticles with polyethylene glycol present in the monolayer arise. 
   4.3 Conclusions 
 Preliminary in vivo toxicity, biodistribution, and clearance experiments were conducted 
in murine models with previously identified antibacterial gold nanoparticle conjugate LAL-32.  
Mice injected with 60 μM LAL-32 succumbed to renal failure at this dosage, while a lower 
Table 4.1.  Titration of polyethylene glycol into the 
monolayer of gold nanoparticle conjugate LAL-32. 
Reaction # PEG:Gold* Yield, umoles MIC99.9 
1 0 0.006 0.25 
2 5 0.006 0.25 
3 10 0.005 0.25 
4 15 0.005 0.25 
5 20 0.004 0.25 
6 25 0.003 0.25 
7 30 0.002 0.25 
All reactions (0.0296 μmoles gold nanoparticles 
initially) contained the original feeds of thiols 
glutathione, cysteamine, and 3-mercapto-1-propane 
sulfonate of 33:1 thiol:gold molar ratio, 46:1, and 33:1, 
respectively on ~2.0 nm diameter pMBA gold 
nanoparticles.  Reaction #1 is the original LAL-32, 
subsequent reaction include polyethylene glycol (PEG) 
into the monolayer. * is a molar ratio between thiol 16 
and gold.  Reactions were conducted in triplicate. 
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injection (10 μM), was tolerated by mice.  Filtration through the liver and kidneys was observed 
to occur for the mice injected with 10 μM LAL-32 as the highest concentrations of gold were 
detected in the liver and kidney at 24 hour post-injection and in the liver and spleen at 2 and 4 
weeks post-injection.  Gold was present in the urine immediately post-injection with no presence 
of gold detected in the urine after 24 hours post-injection.  Gold was present in the blood for up 
to 4 weeks post-injection.  Given previous observations that polyethylene glycol attached to the 
surface of gold nanoparticles has the ability to improve in vivo circulation lifetimes and decrease 
toxic effects of gold nanoparticles
11
, thiol 16 was introduced into the monolayer of LAL-32 gold 
nanoparticles to generate gold nanoparticle conjugate LAL-32P.  LAL-32P, which was verified 
to still exhibit antibacterial activity, with an MIC99.9 of 250 nM against E. coli, was then injected 
into mice.  An immediate reduction in toxicity of the 60 μM injection of LAL-32P was noted as 
compared to the original LAL-32.  While detailed biodistribution studies of these mice are 
pending, mice injected with 60 μM LAL-32P did not exhibit renal failure within 24 hours post-
injection.  This is an example of the ability to tune the pharmacokinetic properties of gold 
nanoparticles utilizing place exchange reactions.  The initial toxicity of LAL-32 was relieved 
through the addition of polyethylene glycol to the surface of gold nanoparticles.  These studies 
demonstrate another advantage of the gold nanoparticle therapeutic platform, where if an initial 
gold nanoparticle formulation has poor pharmacokinetics, another thiol can be conjugated to the 
gold nanoparticle surface in order to relieve the issue. 
   4.4 Future Directions 
 Gold nanoparticle conjugate LAL-32 was previously discovered to have antibacterial 
properties, with an MIC99.9 value of 250 nM against E. coli.  LAL-32 also displayed a therapeutic 
index of 400, indicating that LAL-32’s mode of action was not general membrane disruption.  
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The studies presented here indicate that LAL-32 is toxic in murine models when mice were 
injected with 60 μM LAL-32, while mice injected with 10 μM LAL-32 were observed to have 
liver and kidney filtration.  The immediate toxicity of the 60 μM injection of gold nanoparticles 
was relieved with the addition of thiol 16 into the monolayer of LAL-32 gold nanoparticles.  
Once the biodistribution of LAL-32P is determined, further steps can be taken.  For example, 
analysis of the in vivo effects of each thiol, glutathione, cysteamine, and 3-mercapto-1-propane 
sulfonate conjugated on gold nanoparticles separately can be conducted.  The effects of LAL-32 
with more polyethylene glycol chemical functionality attached to the gold nanoparticle 
monolayer can also be assessed to further tune the pharmacokinetic properties of gold 
nanoparticles.  
   4.5 Experimental Methods 
Synthesis of gold nanoparticles 
p-mercaptobenzoic acid-capped gold nanoparticles (p-MBA-Au) were synthesized as previously 
described.
1
 A solution of 11.1 mM HAuCl4 (SigmaAldrich), 37.8 mM p-mercaptobenzoic acid 
(p-MBA) (TCI-America), 178 mM NaOH in 55.6 % (v/v) aqueous methanol was prepared and 
allowed to equilibrate for 24 hours with constant stirring. Fifty mL of this solution (0.556 
mmoles of Au
3+
) were diluted to a final Au
3+ 
concentration of 0.48 mM with the addition of 260 
mL methanol and 740 mL water.  The Au
3+ 
was reduced with the addition of 10 mL of 0.25 M 
NaBH4 (SigmaAlrich). The final methanol concentration was adjusted to 24.8% with the addition 
of 100 mL of water.  The reduction of gold was allowed to proceed for 48 hours at room 
temperature with constant stirring.  Gold nanoparticles were precipitated with the addition of 68 
mmoles of NaCl and 500 mL of methanol (final methanol concentration of 47 % v/v) followed 
by centrifugation at 3200 RCF for five minutes. The precipitated nanoparticles were 
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reconstituted in water. The concentration was measured by UV-visible spectroscopy, using the 
ε510 nm of 409, 440 M
-1
cm
-1
.  Further, it was noted that the source of reagents for this synthesis is 
important to the preparation.  Ensuring that reagents were not stored with other chemicals that 
could react or contaminate them was also critical. Transmission electron microscopy (TEM) was 
used to determine the average size of the particles. 
Place exchange reactions 
One-pot place exchange reactions were conducted with 7.4 μM gold nanoparticles in 4 
mL of 20 mM pH 9.5 sodium phosphate buffer.  Feed ratios of thiols were modified to increase 
activity of the resultant nanoparticle conjugates and are as follows: thiols 5, and 8 were utilized 
in 33X molar excess of gold nanoparticles, while thiol 6 was utilized at 46X molar excess of gold 
nanoparticles.  Reactions involving thiol 16 are summarized in Table 4.1.  Reactions were placed 
on a plate shaker and agitated for 24 hours at 19°C.  The exchange product was harvested 
through the addition of 40 mmoles of NaCl and a volume of methanol equal to that of phosphate 
buffer and added salt. Reactions were centrifuged at 3200 RCF for 30 minutes.  Precipitated 
nanoparticles were resuspended and precipitated with the addition of NaCl and methanol two 
times to remove excess unreacted thiol.  Particles were allowed to dry to completion overnight at 
room temperature and resuspended in water and washed with water over a 10K MWCO 
centricon filter to remove excess salt and thiol.  As the molar extinction coefficient for gold 
nanoparticles in this size regime does not change considerably (2.33 x 10
5
  L/mol
3
 cm and 1.29 x 
10
6
 L/mol
3
 cm for 1.3 nm and 2.7 nm diameter gold nanoparticles).
1,2
, the extinction coefficient 
reported above for 2.2 nm diameter particles was used to prepare solutions of LAL-32 for 
bacterial growth inhibition assays. UV-visible spectroscopy confirmed that the major product in 
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the synthesis of LAL-32 consisted of particles with similar visible light extinction characteristics 
to the starting pMBA-Au nanoparticles.  
Bacterial growth inhibition assays 
Minimal inhibitory concentration assays were conducted with gold nanoparticle 
conjugates prior to injection into mice to verify that the injected product was still active against 
E. coli.  Briefly, inoculation of E. coli into 3 mL of Mueller-Hinton broth (Fisher) was carried 
out by touching the top of 4 well isolated colonies of E. coli (ATCC 25922) from a Mueller-
Hinton agar (Fisher) plate with an inoculation loop.  The culture was allowed to grow at 37 °C, 
225 rpm for 4 hours after which it was diluted to 1 x 10
6
 CFU/ml in Mueller-Hinton broth.  
Equal volumes of diluted inoculum and nanoparticle sample (adjusted to the correct assay 
concentration in Mueller-Hinton broth) were mixed to make the final inoculum concentration 5 x 
10
5
 CFU/ml.  Samples were incubated at 37 °C, 225 rpm for 18 hours.  End points were 
determined by colony counting on Mueller-Hinton agar after dilution of each sample in PBS and 
incubation of the plates at 37 °C for 24 hours.  
Animal Models 
 Murine models were conducted under the IRB IACUC protocol 1110.01, approved on 
11/2011.  All experiments were conducted under these guidelines.  Animals were housed in a 
Vanderbilt Division of Animal Care (DAC) facility, fully certified by the Association for 
Assessment and Accreditation of Laboratory Animal Care (AAALAC). Animals were housed 
under supervision of full-time veterinarians and staff.   All procedures performed were 
previously approved by the University of Colorado Animal Care and Use Committee (IACUC 
protocol #1110.01). BALBc/cAnNHsd mice, 5-6 week, female, weighing 15-16 g, were 
purchased from Harlan Laboratory. All animals were allowed 1 week for acclimation prior to 
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experimentation. Nanoparticles were prepared in sterile phosphate-buffered saline (n = 15 
mice/concentration group) and injected subcutaneously. Dosage concentrations were 0 µM 
(saline only), 10 µM, and 60 µM in a 200 μL total volume of PBS. Blood was drawn via 
submandibular bleeding techniques
15
, in compliance with our protocol and bleeding guidelines 
for mL/kg body weight per week
16
.  Urine was collected on cellophane with special precaution to 
avoid fecal contamination
17
.  Mice were euthanized (n=5 per euthanasia point/concentration 
group) at 24 hours, 2 weeks, and 4 weeks for organ distribution data.  Mice were euthanized via 
CO2 asphyxiation, followed by cervical dislocation.  The amount of gold present in the urine, 
blood, and various organs determined from 5 mice per concentration per time point.  This 
experimental section from Dr. Carrie Simpson. 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
 Fluid and tissue samples were prepared as described in Simpson et al.
14
 with 
modifications. A 10 µL standard blood/urine sample was used due to limitations in fluid 
collection. The fluid sample was then added to a 4.5 mL solution of distilled water. To this was 
added 0.5 mL of hydrochloric acid (10% HCl dilution, Optima grade, Fisher Scientific) (total 
dilution 500:1 solution: blood/urine). Organ samples were excised, weighed, and digested in 
nitric acid (Optima grade, 70%). The samples were then heated to dryness, at which point the 
remnants were transferred to a solution of 4.5 mL distilled water. To this solution was added 0.5 
mL hydrochloric acid (10% HCl dilution, Optima grade, Fisher Scientific) as described by 
Sadauskas et al.
18
 All samples were then analyzed in duplicate by ICP-MS for gold content using 
a standard calibration as well as the addition of an internal standard (Indium). A blank and three 
standards were used for calibration. A 1000 ppm gold standard was made in house from 99.99% 
pure gold shot, diluted to 0.5 L. A standard check was made using a 10 ppm multi-element 
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standard (SPEX CertiPrep). A 60 second rinse with 4% HCl was used between every standard 
and sample. Analyses of diluted fluid and tissue samples were performed on a Perkin Elmer 
SCIEX ICP-MS (Model # Elan DRC-e) at the University of Colorado Laboratory for 
Environmental and Geological Sciences (LEGS).  This experimental section from Dr. Carrie 
Simpson. 
 
Many thanks to Dr. Carrie Simpson and Candice Smith for conducting the murine models and 
generating in vivo biodistribution and clearance plots. 
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